# British Association of Dermatologists 90th Annual Meeting

MANCHESTER CENTRAL 6th – 8th July 2010



Final Programme



# ELIDEL<sup>®</sup>: Tough on eczema, not on skin

In mild to moderate eczema where topical steroids can be a problem, ELIDEL® delivers rapid relief from itch.<sup>2</sup> ELIDEL®'s low potential to cause skin atrophy<sup>3</sup> means it can be used on sensitive face and neck areas in both adults and children over two years old.1



UK Abbreviated Prescribing Information. Elidel® 1% cream (pimecrolimus). Please refer to the ELIDEL® Summary of Product Characteristics for full prescribing information. **Presentation:** Whitish, homogenous cream containing 1% w/w pimecrolimus. **Indications:** Mild or moderate atopic dermatitis (eczema) in patients aged 2 years and over where treatment with topical corticosteroids is either inadvisable or not possible: short-term treatment of signs and symptoms of atopic dermatitis and long-term intermittent treatment for prevention of progression to flares. **Dosage and administration:** ELIDEL cream should be initiated by physicians experienced in the treatment of atopic dermatitis. Discontinue if no improvement after 6 weeks or disease exacerbation. <u>Adults</u> dermatitis. Discontinue if no improvement after 6 weeks or disease exacerbation. <u>Adults</u> and children aged 2 years and over; apply a thin layer of cream to the affected skin twice daily. Rub in gently and completely. Continue until signs and symptoms have resolved, then discontinue. ELIDEL cream may be used on all skin areas, excluding mucous membranes. For long-term intermittent treatment, apply at first signs and symptoms have resolved, then discontinue. Teatment should be intermittent, short-term and not continuous. Emollients can be applied immediately after using ELIDEL cream. <u>Elderly patients</u>: clinical studies did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. **Contraindications:** Hypersensitivity to pimecrolimus, other macrolactams or excipients of ELIDEL cream. **Precautions:** May cause mild and transient application site reactions e.g. warmth and/or burning sensation. Avoid contact with eyes and mucous membranes. If accidentally applied to these areas, cream should be thoroughly wiped and/or rinsed off with water. Contains cetyl alcohol, stearyl alcohol and propylene glycol, which may cause skin reactions/irritation. ELIDEL stearyl alcohol and propylene glycol, which may cause skin reactions/irritation. ELIDEL should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that causes immunosuppression. Do not use concomitantly with patients on therapy that causes immunosuppression. Do not use concomitantly with topical corticosteroids or other anti-inflammatory products. Cases of malignancy, including cutaneous and other types of lymphoma, and skin cancers have been reported. However, patients with atopic dermatitis treated with ELIDEL have not been found to have significant systemic pinecrolimus levels. Long-term effect on the local skin immune response and on the incidence of skin malignancies is unknown. ELIDEL should not be applied to potentially malignant or pre-malignant skin lesions, or to areas affected by acute cutaneous viral infections (herpes simplex, chicken pox). Clear infections at treatment sites before application. Increased risk of herpes simplex virus skin infection and eczema herpeticum.

CATE

If herpes simplex virus skin infection develops, discontinued ELIDEL until the infection has cleared. Increased risk of skin bacterial infections (impetigo) in patients with severe atopic dermatitis. Not recommended in patients with erythroderma or Netherton's syndrome. Do not apply under occlusive dressings. Not recommended during pregnancy or breast For apply under occusive disease, Not recommended utility pregnations of measurement-free feeding. In patients with extensive disease, administer vaccinations during treatment-free intervals. Avoid excessive exposure of skin to ultraviolet light. Avoid therapy with PUVA, UVA or UVB during treatment. **Undesirable effects:** Application site reactions reported by 19% of ELIDEL patients and 16% of patients in the control groups. These reactions generally occurred early in treatment, were mild/moderate and of short duration. <u>Very</u> <u>common (>1/10):</u> application site burning. <u>Common (>1/10).</u> application site reactions (irritation, pruritus, erythema), skin infections (folliculitis). <u>Uncommon (>1/1,000,</u> <1/100): furuncle, impetigo, herpes simplex, herpes zoster, herpes simplex dermatitis <<u>c1/100</u>; turuncle, impetigo, herpes simplex, herpes zoster, herpes simplex dermatitis (eczema herpeticum), molluscum contagiosum, skin papilloma, application site disorders such as rash, pain, paraesthesia, desquamation, dryness, oedema, and condition aggravated. Quantities and basic NHS price (excl. VAT): 30g tube, £19.68; 60g tube, £37.41; 100g tube, £59.07. Marketing authorisation number: PL 0010/0659. @ denotes registered trademark. Legal category: POM. Full prescribing information is available on request from: Novartis Pharmaceuticals UK Ltd., Frimley, Business Park, Frimley, Camberley, Surrey GU16 7SR. Telephone (01276) 698370. Fax (01276) 698449. Date of preparation: 10th September 2007.

Adverse events should be reported. Reporting forms and information can be found at www.vellowcard.gov.uk Adverse events should also be reported to Novartis (01276) 698370

References: 1. ELIDEL® SmPC. Novartis Pharmaceuticals UK Limited. 2. Meurer M, Fartasch M, Albrecht G, *et al. Dermatol* 2004;**208**:365–372. 3. Queille-Roussel C, Paul C, Duteil L, *et al. Br J Dermatol* 2001;**144**:507–513.

Date of preparation: January 2009. FI 109-001



# INDEX



Accommodation	6 - 7
Accompanying persons	8
Additional meetings	48
Badges	8
Banking	8
Business Services	8
Catering	8
Certificates of attendance	8
Childminding / Babysitting	8
Cloakroom	8
Committee meetings	15
Continuing Professional Development (CPD)	) 8
Delegate bags	8
Evaluation form	9
Exhibition	9
Exhibition quiz	9
Exhibition plan	13
First aid	9
Map of Manchester	59
Meetings Calendar	60
Messages	9
Organising Committees	4
Parking	9
Patient support groups	9
Payment of registration fees	10
Poster exhibition	10
Posters	49 - 55
Programme index	16
Registration desk	10
Restaurants	10
Satellite Symposia	56 - 58
Social events	14
Speaker preview	10
Special interest groups	10
Sports activities	14
Taxis	11
Transport – to and from Manchester	11
Venue Plan	12
Welcome to Manchester	5

MONDAY OVERVIEW	17
DermSchool	18
Trainee pre-conference session	19
SAS Session	20
TUESDAY OVERVIEW	21
CPCs –Joint BAD / BSD	22 - 23
Plenary Session	23 - 24
British Society of Cutaneous Allergy (BSCA)	25 - 26
British Society for Paediatric Dermatology (pm)	27 - 28
Historical	29
British Society for Dermatopathology (BSD)	30 - 31
WEDNESDAY OVERVIEW	33
Plenary session am	34
Plenary session – Medical Dermatology	35
BAD and BDNG Joint Meeting	36
British Society for Dermatological Surgery (BSDS)	37 - 39
British Photodermatology Group (BPG)	40 - 41
THURSDAY OVERVIEW	43
Plenary Session Professor's & Registrars' forum	44 - 45
CPD update	45 - 46
KEYNOTE LECTURES	
Tuesday	
Professor Frank Nestle	24
Sir Leszek Borysiewicz	24
Wednesday	_
Dr Jean Bolognia	34

# Dr Jean Bolognia 34

## Thursday

Dr Joseph Jorizzo	45
Professor Sarah Thomas	46

#### PAGE NUMBER



# **CONFERENCE & EVENT SERVICES**

Mr Christopher Garrett – Conference & Event Services Manager Mrs Marie Elwér – Finance and Conference Administrator Miss Jenna Sanders – Events Coordintor Miss Sally-Ann Koomson – Marketing & Events Coordinator

> British Association of Dermatologists 4 Fitzroy Square London W1T 5HQ Tel: +44 (0)20 7391 6358 Fax: +44 (0)20 7388 0487 Email: conference@bad.org.uk

# **ORGANISING COMMITTEE**

Dr Stephen Jones – Chair Professor Alex Anstey Miss Marilyn Benham Dr David J Eedy Mr Chris Garrett Dr Mark Goodfield Mrs Catherine Hanaway Professor Eugene Healy Dr Glenda Hill Dr Laura Proudfoot Dr Jane Sterling

# **SCIENTIFIC COMMITTEE**

Dr Stephen Jones – Chair Dr Alison Bedlow Dr Claire Fuller Dr Mark Goodfield Dr James Langtry Dr Rob Lister Professor Edel O'Toole Dr Jane Sterling Dr Saleem Taibjee Dr Mike Tidman Dr Maureen Walsh

# **JUDGING COMMITTEE**

Dr Mike Arden-Jones - Chair Dr Sara Brown Dr Richard Goodwin Dr Philip Hampton Dr Jenny Hughes Dr Katie Lacy Dr Richard Logan Dr Richard Meyrick-Thomas Dr Kate Orteu Dr John Reed

# ACKNOWLEDGEMENTS

The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.



# **A WARM WELCOME TO MANCHESTER 2010**

The 90th Annual Meeting of the BAD will see us return to the city of Manchester, the venue for the 2006 meeting. The Manchester Central Convention Complex (MCCC) has undergone a re-branding exercise and also significant renovation work since 2006 to keep it at the cutting edge of conference centre design. The venue now has excellent facilities, including a spacious auditorium for plenary sessions as well as ample space for exhibitors and for meetings of every conceivable size.

Situated within the city centre, the MCCC is within easy reach of hotels, restaurants and the venues for social events to be staged during the week. As such, it promises to be an ideal base for what promises to be a memorable 90th Meeting.

#### Scientific Programme

In response to member's feedback, the meeting this year has been condensed into three full days with the final CPD session now taking place on the Thursday afternoon. Despite this, the content of the meeting remains first class with all of our usual guest speakers and plenary sessions.

The opening Tuesday afternoon plenary session will see Professor Frank Nestle from London talk on 'From genes to function and therapy in Psoriasis'. He will be followed later that afternoon by Professor Sir Leszek Borysiewicz, Chief Executive of the Medical Research Council (MRC) speaking on the topic of Research. Wednesday's programme will incorporate Dr Jean Bolognia of New Haven, USA addressing the audience with an 'Update on cutaneous side effects of chemotherapy'. The final guest lecture will come from Professor Sarah Thomas on Thursday afternoon talking on 'Current thinking in medical education'.

The Arthur Rook Oration this year will be delivered by Dr Joseph Jorizzo, from North Carolina, USA, presenting on 'Neutrophilic vascular reactions' and will occur after the Professors and Registrars forum on the Thursday morning which this year features Professors Chris Griffiths, Alex Anstey and Edel O'Toole.

*Medical Dermatology* continues to feature strongly in the programme with a dedicated session on Wednesday afternoon. We have Satellite Symposia each day and will continue with the poster viewing slot before the AGM on Wednesday morning. The meeting will finish with the popular CPD session on Thursday afternoon.

Our colleagues from the British Dermatological Nursing Group (BDNG) will have a busy academic programme in parallel with ours and will join us for the Joint Session on Wednesday afternoon.

Detailed times can be found in this brochure.

#### Social Programme

The condensed format of the meeting has meant some changes to the usual social programme. The Welcome Reception will be held within the Exhibition hall at the MCCC on the Tuesday evening offering a unique chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. This format has proved popular for many years at major International meetings and lends itself to a great social occasion. The reception will begin after the final session finishes at 18:00 and will leave time for attendees to attend other functions or dine socially afterwards.

The Annual Dinner will be held at the Manchester Town Hall on the Wednesday evening. Completed in 1887, this most impressive neo-Gothic building is acknowledged as a masterpiece in its own right. Places will be limited so book early to avoid disappointment.

Enjoy the meeting!

Stephen Jones Clinical Vice President (2008-2010)





# ACCOMMODATION

# HOTEL RESERVATION FORM

# The 90th Annual Meeting of the British Association of Dermatologists / The 20th Annual Meeting of the British Dermatological Nursing Group 2010

Marketing Manchester is the official hotel booking service for: **The 90th Annual Meeting of the British Association of Dermatologists / The 20th Annual Meeting of the British Dermatological Nursing Group 2010** Tuesday 6th - Thursday 8th July 2010, Manchester Central

To book online, please visit: www.conferencebookings.co.uk and use the Event Reference: MNCBAD2010

Please return to: Carver's Warehouse, 77 Dale Street, Manchester, M1 2HG Telephone: **0871 2262 467** If you have any queries please e-mail **abs@marketing-manchester.co.uk** 

The application deadline is **FRIDAY 18 JUNE 2010**. If you wish to apply for accommodation after this deadline has expired, Marketing Manchester will endeavour to meet your requirements, but requests will be purely on an ad hoc basis and preferred accommodation and rates cannot be guaranteed.

**BLOCK CAPITALS PLEASE** 


\* Entry required

TITLE*	SURNAME*		FORENAME*		
ORGANISATION*					
ADDRESS*					
POSTCODE			E-MAIL*		
TELEPHONE FAX			FAX		
ARRIVAL DATE*	ARRIVAL DATE* DEPARTURE DATE*				
NO. OF EVENINGS			NO. OF PERSONS		
Single Occupancy	(1 person)	Double Oc	ccupancy (2 persons)	Twin Occupancy (2 persons)	
(A Double room for	sole occupancy cannot be	e guaranteed)			
PLEASE INDICATE	ANY SPECIAL REQUIRE	MENTS (Proforma Invoice	e etc)		
Please tick if you	require dinner				
FURTHER INFORM	IATION (Please indicate	e your preferred hotels fro	om the selection attached)		
1st choice					
2nd choice					
3rd choice					
Guarantee ONLY					
Credit/debit card type			Valid from date         Expiry date		
Card no Name on card					
Please indicate here if you do <b>NOT</b> wish to remain on the Marketing Manchester database					
I have read and acknowledge the terms and conditions (please see overleaf)					
Signed (authorised sig	gnatory)			Date	



# ACCOMMODATION

## The 90th Annual Meeting of the British Association of Dermatologists / The 20th Annual Meeting of the British Dermatological Nursing Group 2010 Tuesday 6th - Thursday 8th July 2010, Manchester Central



Map not to scale

ACCOMMODATION

Hotel	Star Rating	Car Park	Single Rate B&B	Double Rate B&B
1 Arora International	4	NCP	99.00	109.00
2 Atrium by Bridgestreet	4	NCP	82.00	92.00
3 Britannia Manchester	3	NCP	65.00	85.00
4 City Inn Manchester	4	NCP	99.00	109.00
5 Crowne Plaza Manchester	4	NCP	125.00	135.00
6 Etap Hotel (not city centre)	n/a	NCP	40.00R0	40.00R0
7 Days Hotel	3	NCP	78.50	88.50
8 Hilton Deansgate	4	NCP	139.00	149.00
9 Jurys Inn Manchester	3	NCP	105.00	115.00
10 Macdonald Manchester	4	NCP	115.00	125.00
11 Novotel Manchester Centre	3	NCP	89.00	99.00
12 Park Inn (not city centre)	4	NCP	110	120
13 Premier Inn Manchester Central	n/a	NCP	79.95	87.90
14 Radisson Edwardian	5	NCP	145	155
15 Ramada Piccadilly	3	NCP	80	90
16 The Castlefield Hotel	3	NCP	85	91
17 The Lowry	5	NCP	150.00	160.00
18 The Midland Hotel	4	NCP	135.00	145.00
19 The Palace Hotel	4	NCP	110.00	120.00
20 The Place Apartments	4	NCP	125.00R0	125.00R0
21 The Thistle	3	NCP	100.00	110.00
22 The Weston Hall	Student	NCP	39.50	n/a
	1190			

BB = Bed & Breakfast RO = Room Only (excludes breakfast) T/A = Travel Accommodation INC = Room rate inclusive of VAT Room Rate is Per Night at Single Rate for 1 Person and Double Rate for 2 Persons. VAT = Value Added Tax @ 17.5%.

#### Conditions & Liabilities

• The rates noted are Per Room Per Night and include private facilities WC with bath and/shower, full English Breakfast (Unless otherwise stated) and VAT at 17.5%

Accommodation will be allocated on a first come, first served basis. If your preferred accommodation is not available, a similar standard of accommodation will be allocated from your choices When a delegate completes and returns a "paper" reservations form to Marketing Manchester and the delegate receives email confirmation this then a legally binding agreement.

- Marketing Manchester will send you confirmation of your reservation via email, please ensure you supply an email address to receive your confirmation promptly
- Marketing Manchester acts only as an agent for hotels and other accommodation providers and does not contract a principle. Accordingly, they are not believable for any loss or damage due to or arising from any acts or omissions of persons, firms or companies for Manchening matchester acts only as an agent to index and other accommodation provides and does not contact a specific and accounting, user are not other whom they act as agents. The Bureau shall not be liable to any extent in the event of delay or failure in providing or procuring any services or facilities due to any cause beyond the pr The Bureau stars as an intermediativi in securing accommodation for this event and cannot accept any responsibility for standards of the accommodation provides on the event and the specific accommodation provides and the specific accounting any services or facilities due to any cause beyond the pr

When Marketing Manchester receive a completed reservation form from the delegate concerned and email confirmation and been received by the delegate from Marketing Manch on their behalf and they are liable for any charges that may arise from the reservation. ster - This confirms the delegate has accepted responsibility of the reservation made Your credit card details are not issued to the hotel via Marketing Manchester; they are ONLY a guarantee method not a payment method. Any other additional services directly to the hotel concerned. are not included in your reservation, so any further charges incurred are payable by the individual

- The balance of hotel accounts must be settled on arrival/departure unless alternative arrangements have been agreed in advance DIRECT with the hotel concerned. Marketing Manchester can request a Pro Forma invoice on behalf of a person(s) to be issued to you for settlement of payment, but are not liable if the hotel does not issue this to the requesting person(s). Individuals must advise Marketing Manchester of cancellations/Amendment via either email (abs@marketing-manchester) or by fax (0161 907 3723) not less than 24 hours prior to your arrival date. In the event of the late cancellation, the individual will be liable for the first nights accommodation.



If you would like to book a place on either of the accompanying persons' tours please complete the relevant section of the registration form.

#### **Tuesday 6th July, 14:00 – 17:00** Fee – £20

#### John Rylands Library and afternoon tea

This masterpiece of Victorian Gothic architecture looks more like a castle or cathedral and is a memorial by a devoted wife to her husband, John Rylands, one of Manchester's most successful cotton industrialists. The interior and exterior architecture is beautiful, and exhibitions include illuminated medieval manuscripts. This will be followed by afternoon tea and a visit to either the Town Hall or Art Gallery.

#### Wednesday 7th July, 09:30 - 17:00

Fee - £40 (lunch and tour included)

#### Tatton Park

Tatton Park is one of the UK's most complete historic estates and is set in acres of rural grounds. Enjoy a tour of the Mansion House followed by Lunch in Lord Egerton's apartment which overlooks the gardens and extensive countryside. Then meet the Head Gardner at the property for a tour of the gardens.

#### We regret that neither accompanying persons nor children/babies are permitted entrance to the exhibition areas.

## BADGES

Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. In the event that you lose your badge, a replacement must be obtained at the registration desk immediately.

## **BANKING**

Aleefs Newsagent (2min walk) next door to Starbucks straight on out of the front entrance. Barclays cash point only (5min walk) located on Deansgate opposite Sainsbury's.

Barclays Bank (5-8min walk) Moseley Street.

## **BUSINESS SERVICES**

Photocopying (10p per copy black and white and 50p per colour A4) faxes and a telephone line will be available in the organisers office.

The phone number for the organisers office is 0161 834 3339 and the fax number is 0161 834 8622.

## CATERING

Lunch and all scheduled refreshment breaks will be served from designated points in the exhibition hall of the Manchester Central Convention Complex. If the nearest catering point is not open, staff will direct you to the next most convenient point.

## CERTIFICATES OF ATTENDANCE

Certificates of attendance will automatically be sent to all attendees after the meeting.

# CHILDMINDING/ BABYSITTING

There will be no crèche facilities at the meeting. Please approach your hotel directly for a babysitting service or to make alternative child care arrangements. Please note that babies and children cannot be admitted to the exhibition areas or social events.

There is a crèche facility at the town hall. The contact details are:

St. Peters Children's Centre Myriam Bradshaw 0161 234 3246

## **CLOAKROOM**

The cloakroom will be located in the Foyer at the Manchester Central Convention Complex. There will be no charge. Guests will also be able to store luggage on the day of departure.

## **COMMITTEE MEETINGS**

A programme of the scheduled committee meetings can be found on page 15.

## CONTINUING PROFESSIONAL DEVELOPMENT CREDITS (CPD)

This event will be approved for External credit for the CPD Scheme of the Federation of Royal Colleges of Physicians of the UK. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations. Participants should only record the number of hours they attended.

## **DELEGATE BAGS**

The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment.

Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this.





Following delegate feedback from last years meeting delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottles and has the BAD Logo on the side.

We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD 'Bag for Life'.

At future annual meetings we will have a stock supply of these bags but would encourage delegates to bring their own.

## **EVALUATION FORM**

This year's evaluation form will be on-line and all attendees will be sent a link after the meeting.

Thank you in advance for taking the time to complete it, as it is an invaluable tool for us in organising future meetings.

## **EXHIBITION**

The exhibition will be located in the Central 2 Hall of Manchester Central and will be open at the following times:

 Tuesday 6th July
 10:00 – 19:30

 Wednesday 7th July
 08:30 – 17:30

 Thursday 8th July
 08:30 – 14:30

## **EXHIBITION QUIZ**

Exhibition quiz forms will be included in delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain 4 answers from the patient support groups, please note you only need 4 from any of the Patient Support Groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 8th July. The prizes will be announced after the meeting.

## **EXHIBITORS**

Please see page 13 for a full list of exhibitors and an exhibition plan.

## **FIRST AID**

The First Aid Suite is situated by the exhibitor storage area in the exhibition hall and will be staffed by Manchester Central. The first aid mobile phone number is 07527 254221.

## **MESSAGES**

A delegate notice board will be situated adjacent to the registration desk, where all delegates' messages will be displayed.

## PARKING

Once you have travelled into the city by car, then the best place to park is the NCP car park on site at Manchester Central. It is open 24 hours and the address details for sat nav are: Lower Mosley Street, Manchester, M2 3GX.

For more information on NCP car parks in Manchester, visit www.ncp.co.uk or telephone 0845 050 7080.

# **PATIENT SUPPORT GROUPS**

The following patient support groups will be represented at the meeting and will have stands in the exhibition hall:

#### Tuesday 6th July, Wednesday 7th July Only

British Porphyria Association

Dystrophic Epidermolysis Bullosa Research Association (DebRA) Gorlin Syndrome Group

#### Tuesday 6th July, Wednesday 7th July, Thursday 8th July

Alopecia UK **Dowling Club** Ichthyosis Support Group Neurofibromatosis Association NHS Evidence – skin disorders Nodular Prurigo UK Psoriasis and Psoriatic Arthritis Alliance Psoriasis Scotland Arthritis Link Volunteers (PSALV) Skin Camouflage Network The British Association of Skin Camouflage The British Red Cross The Hyperhidrosis Support Group The Lymphoedema Support Network The Psoriasis Association **UK Dermatology Clinical Trials Network Vulval Pain Society** 

#### Wednesday 7th July, Thursday 8th July Only

Latex Allergy Support Group Scleroderma Society Vitiligo Society XP Support Group

# In addition, the following groups will have stands within the exhibition area:

BADBIR

British Dermatological Nursing Group British Journal of Dermatology / CED British Skin Foundation Community Dermatology & IFD Historical Collection e-Dermatology



# PAYMENT OF REGISTRATION FEES

We would prefer delegates to pay by cheque (pounds sterling drawn on a UK bank only or by sterling bank draft) made payable to the 'British Association of Dermatologists'. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. **American Express cannot be accepted**.

## **POSTER EXHIBITION**

The poster exhibition will be located within Central 2 of Manchester Central. The posters will be numbered and a list is provided at the back of this programme.

Posters should measure a maximum of 1.5m high x 1m wide (portrait) and must be mounted with Velcro. Presenters will be able to mount their posters from 10:00 on Tues 6th July. Posters should not be removed until 14:00 on Thursday 8th July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

## **REGISTRATION DESK**

Upon arrival please make your way to the registration desk located in the Manchester Central Foyer. It will be staffed by the BAD team during the following hours:

Monday 5th July	08:30 - 18:00
Tues 6th - Thurs 8th July	07:30 – 18:00

## RESTAURANTS

Below are the details of a few locally recommended restaurants.

Beluga (Modern European) www.belugaonline.co.uk	Tel: 0845 058 2604
<b>Opus One Restaurant</b> Radisson Edwardian	Tel: 0845 058 2654
Tiger Tiger (Grill)	Tel: 0845 058 2630
The Printworks www.tigertiger.co.uk	
Old Orleans Cocktail Bar & Grill	Tel: 0845 058 2653
The Printworks	

www.oldorleans.com

#### Bar 38

Tel: 0161 835 3076

Peter Street

www.bar38manchester.co.uk

## **SATELLITE SYMPOSIA**

The following companies will be holding satellite symposia at the meeting:

#### **Tues 6th July**

13:15 – 14:15	Abbott
13:15 – 14:15	Pfizer

#### Wednesday 7th July

13:15 – 14:15	Janssen-Cilag
13:15 – 14:15	La Roche-Posay

#### **Thursday 8th July**

13:15 – 14:15 **Schering Plough** 

## **SOCIAL EVENTS**

Please see Social Programme (Page 14).

## **SPEAKER PREVIEW**

Speaker preview will be located in Central Room 4 in the foyer at Manchester Central, please ask at the registration desk for directions. All presenters must take their presentations to speaker preview at least two hours prior to their presentation. Data projection (PowerPoint) will be available.

## **SPECIAL INTEREST GROUPS**

The following Special Interest Groups will hold their meetings during the week of the conference. All special interest group meetings will take place in Manchester. Their full programmes are featured at the back of each days full programme.

#### **Tues 6th July**

British Society of Cutaneous Allergy 09:00 - 12:30 (Page 25 - 26)

British Society for Paediatric Dermatology 09:00 – 12:45 (Page 27 – 28)

Historical 11:00 – 12:00 (Page 29)

British Society for Dermatopathology 15:00 – 18:00 (Page 30 - 31)

Wednesday 7th July British Society for Dermatological Surgery 14:30 – 18:00 (Page 37 – 39)

British Photodermatology Group 14:30 – 18:00 (Page 40 – 41)



## TAXIS

Service

• Radio Cars Manchester	0161 236 8033
• Mantax Taxis Ltd	0161 230 3333
• Manchester Minibus Taxis	0161 850 0568
<ul> <li>Manchester Cars</li> </ul>	0161 237 3383
<ul> <li>Manchester Limousine</li> </ul>	0161 49 20 307

## TRANSPORT

- IN AND AROUND MANCHESTER
- TO AND FROM MANCHESTER CENTRAL

#### www.manchestercentral.co.uk/getting-here

Manchester Central is in the heart of Manchester city centre in the North West of England. Located in the centre of the UK, the city is served by strong road, rail and air links, making it an easily accessible location for visitors from all over the world.

# By road

Manchester is at the heart of the Northwest's motorway network with easy access from all directions onto the M60, the city's orbital motorway. Once on the M60 exit at Junction 12 and join the M602 signposted towards the city centre. Follow the A57 straight on from the end of the M602 passing under a railway bridge before taking the left hand exit to merge onto the A56 Bridgewater Way. Turn right onto Whitworth Street West at Deansgate station and then turn left onto Albion Street. The entrance to the Manchester Central Car Park is through the next set of traffic lights on the left, opposite The Bridgewater Hall.

If you are using sat nav, type in M2 3GX which will take you to the car park at Manchester Central.

The following links may be useful in helping to plan your journey by car:

- www.theaa.com
- www.highways.gov.uk

# By rail

Manchester has direct rail connections to all major UK cities – London is just over two hours away by train. Services come into the city at either Piccadilly or Victoria station, both of which connect to Manchester's Metrolink light-rail system which provides easy access to all parts of the city centre. Take the Metrolink from either Piccadilly or Victoria (in the Altrincham or Eccles direction) and alight at St Peter's Square, which is within a 5-minute walk of Manchester Central. You can also take advantage of the free Metroshuttle bus that travels between the two stations across the city centre.

For information on train services to Manchester, please use the following links: www.virgintrains.co.uk

www.nationalrail.co.uk

# By air

Manchester airport is a major international air traffic hub with frequent scheduled flights to the majority of key UK, European and international destinations. It is 9 miles (14.5km) outside the city centre, taking approximately 25 minutes by taxi, or alternatively there is a direct half-hourly express rail service to the city centre that takes approximately 20 minutes. More information on services to Manchester airport can be found at www.manchesterairport.co.uk.


## VENUE

Manchester Central Petersfield Manchester M2 3GX Tel +44 (0)161 834 2700 Fax +44 (0)161 833 3168

http://www.manchestercentral.co.uk



# **Manchester Central Venue Plan**



**VENUE PLAN** 

# **Exhibition Plan**

Company S	tand [	Stand Number
Alopecia UK		PSG 20
<b>3ritish Porphyria Association</b>		PSG 9
<b>3ritish Red Cross</b>		PSG 23
Oystrophic Epidermolysis Bullosa Research Association (DebRA)	losa )	PSG 8
sorlin Syndrome Group		PSG 7
chthyosis Support Group		PSG 10
atex Allergy Support Group		PSG 4
Veurofibromatosis Association	c	PSG 12
VHS Evidence – skin disorders	ş	PSG 15
Vodular Prurigo UK		PSG 21
<sup>5</sup> soriasis and Psoriatic Arthritis	is	PSG 11
Soriasis Scotland Arthritis Link	¥	PSG 2
scleroderma Society		PSG19
skin Camouflage Network		PSG 1
The British Association of		PSG 18
okin camounage The Dowling Club		PSG 22
The Hyperhidrosis Support Group	roup	PSG 16
he Lymphoedema Support Network PSG	letwork	< PSG 17
The Psoriasis Association		PSG 13
JK Dermatology Clinical Trials Jetwork	s	PSG 14
/ittiligo Society		PSG 5
/ulval Pain Society		PSG 6
(P Support Group		PSG 3



Number E15 B7 E20 D20	C1 E1 E1 E1 E1 E1 E1 E1 E1 E1 E1 E1 E1 E1	E19 E24 E13 E10	E4 D6 D15 E16	D4 E12 D10 F1	C12 C13 C13 C13 C13 C13 C13 C13 C13 C13 C13	C3 A7 D14 C16 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3 C3	E3 A4 E18 E25 A3 E11 D16 B8 B8	C7 B9 D1 D1 D1 D1 C6 D1 D1 C4 D1 C4 C4 D1 C4 C4 C5 C6 D1 C6 C7 C7 C7 C7 C7 C7 C7 D2 D2 C7 C7 C7 D2 D2 D2 C7 D2 D2 D2 D2 D2 D2 D2 D2 D2 D2 D2 D2 D2
Stand	uticals Ltd .d International Limited olay	s Ltd	ms (UK) Ltd	C & IFD		e Ftd	य प	ondon) Ltd Ltd
Company 4s Information Systems Abbott Academic Dermatology Activa Healthcare	Alliance Pharmaceuticals Almirall Astellas Pharma Ltd Athrodax Healthcare Interna BAD Historical Display	BAUDIR Basilea Pharmaceuticals Ltd Beiersdorf BJD & CED British Skin Foundation	Brymil Cryogenic Systems (UK) Candela UK Cephalon UK Ltd Clarisonic	CliniMed Ltd Clinique Laboratories LLC Community Dermatology & Cosmetique Active Cranage Healthcare Ltd Crawford Dharm zoutricale 1	Crown of the second sec	Diagenics Ltd Diagenics Ltd Espère Healthcare Ltd Forest Laboratories UK L Galderma (UK) Ltd Healthcare at Home Janssen-Cilag Ltd Janssen-Cilag Ltd Janssen-Cilag Ltd Kensington Consultants LEO Pharma	Lynton M & A Pharmachem Ltd MA Healthcare Meda Pharmaceuticals Ltd Michelson Diagnostics Ltd Mims Dermatology Molnlycke Health Care Priadia Ltd	Reckitt Benckiser Reckitt Benckiser Schering-Plough Ltd Schuco International (London) L Shire Pharmaceucials Ltd SkinBrands Limited SkinBrands Limited Storegy Health Therrakos Thornton & Ross Ltd Therrakos Thornton & Ross Ltd Therrakos Uvistat Wiey-Blackwell Wiey-Blackwell

# EXHIBITION PLAN





# **SOCIAL EVENTS**

#### WELCOME RECEPTION Tuesday 6th July 18:00 – 19:30 Manchester Central

The Welcome Reception will be held within the Exhibition hall on the Manchester Central venue, offering a unique chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. This format has proved popular for many years at major International meetings and lends itself to a great social occasion. Drinks and canapés will be served after the final session finishes at 18:00 and will leave time for attendees to dine afterwards.

#### ANNUAL DINNER Wednesday 7th July 19:30 Manchester Town Hall

The Annual Dinner will be held at the Manchester Town Hall. Completed in 1887, this most impressive neo-Gothic building cost a million pounds and is acknowledged as a masterpiece in its own right. It rises as a Victorian edifice - a monument to the civic pride of the city fathers, reaching 286 feet above Albert Square below. Places will be limited so book early to avoid disappointment.



Manchester Town Hall Annual Dinner venue

# **SPORTS ACTIVITIES**

#### **Tuesday 6th July**

All sports events will be held at venues in and around the city on Tuesday evening. The departure point for all events will be from outside the Manchester Central Convention Centre.

# Bowers-Sneddon-Harman Sailing Competition – 18:00, meet by registration at 17:30

The sailing competition will take place at Elton Sailing Club on the Elton Reservoir in Bury. Limited places will be available and people should bring warm layers and waterproofs. Full details of the event will be sent following registration.

#### Dowling – McCaw Golf Cup – 15:00

A local golf club will host this event. Please note that Green fees will be charged per person. Full details of the event will be sent following registration.

#### Five-a-side Football – 18:00, meet by registration at 17:30

The competition will be held at Powerleague, Manchester Central. The competition is open to everyone, members, non-members, guests and exhibitors. You may apply as a team or individually.

#### Ive Piscatorial (Fishing) Competition

Further details of the event will be sent following registration.

#### Tennis – 18:00, meet by registration at 17:30

The tennis competition will take place indoors at the Manchester Regional Tennis Centre, one of the great sporting legacies of the 2002 Commonwealth Games, located in the heart of the Sportcity complex. Participants should bring their own racquets and proper tennis shoes are required.



# **COMMITTEE MEETINGS**

MON 5TH JU	JLY:	
TIME	MEETING	ROOM
16:00 – 18:00	British Association of Dermatologists Officers	Exchange 4
18:30 – 19:30	National Speciality Trainee Committee	Exchange 2

# TUES 6TH JULY:

TIME	MEETING	ROOM
08:00 - 09:00	British Society for Dermatopathology Exec Committee	Exchange 2
08:00 - 09:00	British Society for Paediatric Dermatology Training Committee	Exchange 6
08:30 - 09:00	The British Society of Cutaneous Allergy (BSCA) AGM (formally the British Contact Dermatitis Society)	Charter 3, 4, 5
10:00 – 12:00	British Teledermatology Society	Exchange 3
11:30 – 13:00	British Skin Foundation Trustees	Exchange 1
13:00 – 14:00	Historical Collection Sub-Committee	Exchange 4 / 5
13:00 – 15:00	Community Dermatology Editorial Board	Exchange 7
14:30 – 15:00	British Society for Dermatopathology AGM	Charter 3, 4, 5
14:30 – 16:30	Clinical Services Committee	Central Room 6
16:00 – 17:00	Therapy & Guidelines	Central Room 7
16:30 – 18:30	BADBRL Management Committee	Central Room 5
17:00 – 18:00	British Society for Paediatric Dermatology Committee	Exchange 2
17:00 – 18:00	Audit & Clinical Standards	Central Room 7
17:30 – 18:30	Dermatology Teachers	Central Room 6
17:30 – 18:30	BAD Session Judging Committee	Central Room 8

# WED 7TH JULY:

	JET.	
ТІМЕ	MEETING	ROOM
11:00 – 13:00	British Association of Dermatologists' AGM (Members Only)	Exchange Auditorium
13:00 – 14:00	British Association of Dermatologists Officers	Exchange 4
13:00 – 14:30	British Society for Dermatological Surgery Committee	Exchange 6
13:00 – 14:30	British Photodermatology Group Committee	Central Room 8
13:00 – 14:30	British Cosmetic Dermatology Group AGM	Exchange 7
14:00 – 15:00	British Association of Dermatologists' Executive Committee	Exchange 2 / 3
14:00 – 16:00	British Journal of Dermatology	Exchange 5
14:00 – 16:00	Health Informatics Sub-committee	Exchange 4
17:00 – 19:30	Senior Skin Group	Exchange 4
17:30 – 18:00	UK Professors Group	Exchange 6
17:30 – 18:00	British Photodermatology Group AGM	Central Room 5, 6, 7
17:30 – 19:00	BAD Session Judging Committee	Central Room 8
18:00 – 18:30	British Society for Dermatological Surgery AGM	Exchange Hall
18:15 – 19:15	e-Learning Reception	Exchange 3

<b>THURS 8TH</b>	JULY:	
TIME	MEETING	ROOM
08:30 - 09:30	Exhibitors' Meeting	Exchange 4
08:30 - 09:30	UK DCTN Trial Prioritisation Panel	Exchange 6
08:30 - 10:30	British Skin Foundation Grants Advisory	Exchange 7
10:30 – 12:00	International Investigative Dermatology 2013 Committee	Exchange 5
13:00 – 14:00	Clinical and Experimental Dermatology Editorial Meeting	Exchange 1
13:00 – 14:30	UKDCTN AGM/Steering Group	Exchange 7
13:00 – 17:00	BAD Session Judging Committee	Central Room 8
15:15 – 17:15	Biologics Steering Group	Central Room 5



# **PROGRAMME INDEX**

#### PAGE NUMBER

MONDAY		
	Overview	17
	DermSchool	18
	Trainee pre-conference session	19
	SAS Session	20
TUESDAY		
	Overview	21
	Clinico-pathological cases – Joint BAD / BSD	22 – 23
	Plenary	23 – 24
	British Society of Cutaneous Allergy	25 –26
	British Society for Paediatric Dermatology	27 – 28
	Historical	29
	British Society for Dermatopathology	28 – 29
WEDNESDAY		
	Overview	33
	Plenary	34
	Medical Dermatology Plenary Session	35
	BAD and BDNG Joint Meeting	36
	British Society for Dermatological Surgery	37 – 39
	British Photodermatology Group	40 – 41
THURSDAY		
	Overview	43
	Professor's & Registrars' Forum	44 – 45
	CPD Session	45 – 46
Additional meetings		48
Bristol Cup posters		49 – 55 56 – 58
Satellite Symposia		56 – 58

Monday 5th	08:00 - 09:00 9:00 - 10.00 10.00	10.00 - 11:00	11:00 - 12:00	12:00 - 13:00		13:00 - 14:00	14:00 - 15:00	15:00 - 16:00	16:00	16:00 - 17:00	17:01	17:00 - 18:00	18:00	18:00 - 19:00	
	08610 0815 0830 0845 0930 0915 0330 0845 1000 1015 1030 1445 1130 1145 1130 1245 1330 1245 1330 1345 1430 1445 1530 1545 1530 1645 1700 1715 1730 1745 1830 1815 1830 1845 1600 1615 1830 1845 1700 1715 1730 1745 1830 1815 1830 1845 1845 1830 1845 1830 1845 1845 1845 1845 1845 1845 1845 1845	5 10:30 10:45 11:00 ① ① ① ①	11:15 11:30 11:45	12:00 12:15 1 ① ①	2:30 12:45 13:00 1 0 0 0 0	3:15 13:30 13:45 14	14:15         14:30         14:4           0         0         0         0         0	15 15:00 15:15 1 ① ①	15:30 15:45 16:00 0 0 0	0 16:15 16:30 16	3:45 17:00 17:1 ① ① ④	15 17:30 17:45 ① ①	5 18:00 18:15 0 0	· 18:30 18:45	
Exchange Auditorium															
Central Foyer						Registration Open									
Central Hall 2						Exhibition Build Up									
Exchange Hall				Welco.	Welcome Lunch	Trainee Pre-conference session	ence session	Tea		Trainee Pre-	Trainee Pre-conference session	ssion			
Charter 3	}	10	DermSchool	chool	DS Career Talks	r Talks	DermSchool	ol							
Charter 4					DS Cryo Workshop	orkshop		;							
Charter 5				I	DS Cryo Workshop	orkshop									
Exchange 1		:		I		SAS Meeting				SAS Meeting					
Exchange 2		,			SAS Lunch			Tea / Coffee						NSTC Meeting	
Exchange 3															
Exchange 4	DS catedino	DS catering			HUNITI SU					BAD O	BAD Officers Meeting				
Exchange 5			20		2										
Exchange 6	DS Posters	DS Posters			D.S. Prosters										
Exchange 7															
Central Room 3						Cloakroom									
Central Room 4						Speaker Preview									
KEY	BAD Special Interest Exhibition / BAD Focus Sessions Groups Posters Committee Session	Additional Non-BAD Groups Meetings	Satellite Symposia	Delegate Information	BDNG Session										

# **MONDAY 5TH JULY – OVERVIEW**





# **MONDAY 5TH JULY – DETAILED PROGRAMME**

		-		
TIME	CODE	PROGRAMME		VENUE
08:30 – 18:	:00	Registration desk open		Central Foyer
09:25 - 1	5:30	DERMSCHOOL PRE-CONFE	RENCE SESSION	CHARTER 3
09:00		<b>Registration and Coffee</b>		
09:25		Introduction Dr Jane Sterling		
	CHAIRS	Dr Mini Singh and Dr Laura F	Proudfoot	
09:30	DE01	Common Skin Diseases (in • Eczema & Acne • Psoriasis • Skin infections	ncluding recent advances tre Dr Stuart Cohen Dr Richard Warren Dr Mini Singh	eatment)
10:30	DE02	Skin in Systemic disease	Dr Sandra Winhoven	
11:00		Coffee Posters		Exchange 4 / 5 Exchange 6 / 7
11:30	DE03	<b>Research in Dermatology</b> Professor Christopher Griffith:	s	
12:00	DE04	Career paths in Dermatol • A Day in the Life • Career Planning	<b>ogy</b> Dr Venura Samarasinghe Dr Tamara Griffiths	
12:30		(	r Lunch	Exchange 4 /5
		½ hour rotations in assigned groups	Career Surgery	Charter 3
			Cryotheraphy Workshop	Charter 4 / 5
	CHAIR	Dr Jane Sterling		
14:00	DE05	<b>Skin Cancer &amp; Surgery</b> Dr Ashley Cooper		
14:30	DE06	Dermatology for Exams Dr Sue Burge		
15:00		Poster Prize		
15:05		Tea		Exchange Hall
		DERMSCHOOL DELEGATES J	DIN TRAINEE SESSION	

**NOTE:** Posters by DermSchool delegates to be on display in the Exchange 6 / 7 room (to include posters by elective prize winners)



# **MONDAY 5TH JULY – TRAINEE PROGRAMME**

12:55 - 18:20	TRAINEE PRE-CONFERENCE SESSION	EXCHANGE HALL
12:15 – 12:55	Welcome Lunch	Exchange Hall
12:55	Introduction – Dr Laura Proudfoot and Dr David de Berker	
13:00	<b>TPC01 Pregnancy dermatosis</b> Dr Karen Gibbon	
13:45	<b>TPC02 Haemangiomas</b> Dr Cameron Kennedy	
14:30	<b>TPC03 SCE Update</b> Dr Richard Groves	
15:00	<b>DermSocs – the BAD Student Group</b> Dr Ketaki Bhate	
15:05	<b>Tea / Coffee</b> Trainees then joined by DermSchool delegates	
15:30	<b>TPC04 Derm Clinics</b> Dr David de Berker & Dr Jonathan Bowling	
16:15	<b>TPC05 Dermoscopy</b> Dr Jonathan Bowling	
17:00	<b>TPC06 Genodermatoses</b> Dr Jemma Mellerio	
17:45	<b>TPC07 Forensic Dermatology</b> Dr Jason Payne-James	
18:15	<b>Dowling Club</b> Dr Mike Beck & Dr Anja Weidmann	
18:20	Close	
19:00 – 23:00	Trainee & DermSchool evening event	Bar 38



# **MONDAY 5TH JULY – SAS PROGRAMME**


13:55 – 17:35 STAFF AND ASSOCIATE SPECIALISTS SESSION

**EXCHANGE 1** 

A tour of the Special Interest Groups

12:15 – 13:00	Registration	
12:15 – 13:00	Welcome Lunch	Exchange 2
13:00	Welcome and Introduction – Dr Glenda Hill	
13:05	<b>Historical Archive</b> Silk Route Dr Paul Yesudian	
13:45	<b>Paediatric Dermatology</b> <b>Neonatal Dermatology</b> Dr Lindsay Shaw	
14:25	<b>Contact Dermatitis Immediate Contact Reactions &amp; Supplementary te</b> Dr Sarah Wakelin	esting
15:05	Tea / Coffee	Exchange 2
15:35	Dermatopathology Amyloidosis-Clinical & pathological variants Dr lan Coulson	
16:15	<b>Dermatological Surgery Update on Lasers</b> Dr Sean Lanigan	
16:55	Photodermatology All you need to know about PLE Dr Jane McGregor	
17:35	Closing remarks	
19:00 – 22:00	SAS evening event	Barbirolli

# TUESDAY 6TH JULY – OVERVIEW





# TUESDAY 6TH JULY – DETAILED PROGRAMME

TIME	CODE	PROGRAMME	VENUE
07:30 – 18:00		Registration desk open	Central Foyer
<b>09:00 - 12:45</b>		BRITISH SOCIETY OF CUTANEOUS ALLERGY (PAGE 25 – 26)	CHARTER 3, 4, 5
09:00 - 12:45		BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY (PAGE 27 – 28)	EXCHANGE HALL
09:30 – 10:28		CLINICOPATHOLOGICAL CASES	Exchange Auditorium
		Joint meeting with the British Society of Dermatopatholog	
	CHAIRS	Dr Maureen Walsh & Dr Robert Lister	
09:30	CPC-1	<b>Multifocal presentation of a rare condition</b> <u>B. Arun</u> , L. Jamieson and E. Stewart	
09:37	CPC-2	<b>Pemphigoid gestationis requiring oophorectomy</b> <u>A. Sinha</u> , S. Darne, P. Barrett, C. Steele and C. Blasdale	
09:44	CPC-3	Blaschkoid Darier disease in association with bullo <u>A. Sherley-Dale</u> , R. Carr and B. Dharma	us pemphigoid
09:51	CPC-4	Familial lichen amyloidosis with partial response to ultraviolet B radiation in the presence of an OSMR and negative RET proto-oncogene mutation <u>A.E. Macbeth</u> , A. Tanaka, N. Nagy, A. Ali, N.J. Levell, J.A. M G.W.M. Millington	gene mutation
09:58	CPC-5	An unusual presentation of systemic AL amyloidos milia formation <u>A. Pink</u> , C. Stefanato and S.M. Breathnach	is: bulla and
10:05	CPC-6	<b>Clinical coexpression of widespread vitiligo, with s</b> <b>psoriasiform change</b> <u>N.C. Chetty</u> , L. Igali, J. Garioch, S. Shah and G.W.M. Milli	
10:12	CPC-7	<b>Tyrosine kinase inhibitor induced palmoplantar ar a class effect</b> <u>A. Fityan</u> , C. Morgan, C.J.M. Stephens and A. Belgi	inular erosions:
10:19	CPC-8	<b>Cutaneous mucormycosis in a patient with acute r leukaemia</b> <u>T.T. Lew</u> , T. Lewis, P. Dunn, N. Pemberton and C. Bertran	-
10:28 – 11:14		Coffee & Exhibition	Central 2
11:00 - 12:00		HISTORICAL COLLECTION SYMPOSIUM (PAGE 29)	EXCHANGE 4, 5
11:14 – 12:40		CLINICOPATHOLOGICAL CASES CONTINUED	Exchange Auditorium
	CHAIRS	Dr Saleem Taibjee & Dr Chris Dobson	
11:14	CPC-9	<b>A rare case of vulval pustulation in rosacea fulmin</b> J. Hafiji, C. Sonnex, E. Rytina and J.C. Sterling	ans



<u>M.G. Khorasgani</u> , P. Mensah, R. Simpson, A. Fletcher, G. S Johnston and K.E. Harman	Saldanha, G.A.
Hepatitis B associated type I monoclonal cryoglob presenting with cutaneous vasculitis, treated with <u>K. Lee</u> , A. Heaton, A-M. Skellett, T. Barker, D. Scott and G	rituximab
Bullous pyoderma gangrenosum and arthritis: clor gene rearrangements in skin and synovium <u>C. Hackett</u> , C. Cunningham, M.F. Doran, G. Cunane and	
Azathioprine hypersensitivity presenting as erythe lesions in a patient with ulcerative colitis L. Paul and V. Goulden	ema nodosum-like
<b>Perniotic lesions as an indicator of coexisting or p disease</b> <u>A. Fogo</u> and J.D. Creamer	otential systemic
'Hands only': two distinctive cases of neutrophilic the hands M.I. Darling, S.J. Fraser, M.E. Mathers and G.M. Kavanagh	
Linear cutaneous lupus erythematosus <u>N. Aldoori</u> and J. Kellett	
Joint BAD/BSD Neil Smith Lecture Interface dermatitis and connective tissue disease Dr Martin Mihm (Boston)	
Lunch & Exhibition	Central 2
Lunch & Exhibition PFIZER SATELLITE SYMPOSIUM (PAGE 56)	Central 2 EXCHANGE HALL
	EXCHANGE
PFIZER SATELLITE SYMPOSIUM (PAGE 56)	EXCHANGE HALL
PFIZER SATELLITE SYMPOSIUM (PAGE 56) ABBOTT SATELLITE SYMPOSIUM (PAGE 56) BRITISH SOCIETY FOR DERMATOPATHOLOGY	EXCHANGE HALL CHARTER 3,4,5 EXCHANGE
PFIZER SATELLITE SYMPOSIUM (PAGE 56) ABBOTT SATELLITE SYMPOSIUM (PAGE 56) BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 30 – 31)	EXCHANGE HALL CHARTER 3,4,5 EXCHANGE HALL Exchange
PFIZER SATELLITE SYMPOSIUM (PAGE 56)         ABBOTT SATELLITE SYMPOSIUM (PAGE 56)         BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 30 - 31)         SCIENTIFIC SESSION - SUBMITTED PAPERS	EXCHANGE HALL CHARTER 3,4,5 EXCHANGE HALL Exchange
PFIZER SATELLITE SYMPOSIUM (PAGE 56)ABBOTT SATELLITE SYMPOSIUM (PAGE 56)BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 30 - 31)SCIENTIFIC SESSION - SUBMITTED PAPERSDr Mark Goodfield & Dr Stephen Jones	EXCHANGE HALL CHARTER 3,4,5 EXCHANGE HALL Exchange Auditorium
PFIZER SATELLITE SYMPOSIUM (PAGE 56)         ABBOTT SATELLITE SYMPOSIUM (PAGE 56)         BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 30 – 31)         SCIENTIFIC SESSION - SUBMITTED PAPERS         Dr Mark Goodfield & Dr Stephen Jones         Official Opening & Welcome - Mark Goodfield         Skin conditions are the commonest new reason per to general practitioners in England and Wales: im education and training	EXCHANGE HALL CHARTER 3,4,5 EXCHANGE HALL Exchange Auditorium

Two unusual cases of antiphospholipid syndrome mimicking

necrotizing fasciitis and periorbital cellulitis

11:21

11:28

11:35

11:42

11:49

11:56

12:03

12:10

12:45 - 14:30

13:15 - 14:15

13:15 - 14:15

14:30 - 18:00

14:30 - 18:00

14:30

14:45

15:00

**CPC-13** 

**CPC-11** 

**CPC-12** 

**CPC-10** 

**CPC-14** 

**CPC-15** 

**CPC-16** 

CHAIRS

0-1

0-2

15:15 0-3 The role of invariant natural killer T cells in psoriasis A.-M. Tobin, A. Hogan, L. Lynch, S. Rogers, P. Collins, D. O'Shea and B. Kirby



15:30 **GL01** 

#### Guest Lecture 1 –introduced by Dr Stephen Jones

Exchange Auditorium

#### From genes to function and therapy in Psoriasis Professor Frank Nestle (London)



16:00 – 16:30		Tea and Exhibition	Central 2, Exhibition Hall
16:30	0-4	Location and regulation of sunbed outlets <u>N. Bowtell</u> , V. Poirier, S. Harris, S. Smith, S. McPhail a	nd J. Verne
16:45	0-5	<b>Teledermatology triage for suspected skin can</b> service quality and effectiveness in a Northern centre A. O'Hagan, R. Black, <u>E. McCallion</u> , C. Ross, L. Godfre and D.J. Eedy	Irish dermatology
17:00	0-6	<b>Demonstration of novel innate immune cells in</b> <u>R.K.H. Mak</u> , C. Hundhausen, E. Botti, K. Grys and F.O	
17:15	0-7	<b>Revertant mosaicism in Kindler syndrome resu transcriptional gene correction</b> J. Lai-Cheong, T. Techanukul, M. Parsons, C. Moss an	-
17:30 – 18:00	GL02	Guest Lecture 2 –introduced by Prof Alex Anstey	Exchange Auditorium
		<b>Research and all that goes with it in the UK</b> Sir Leszek Borysiewicz (London)	
		Sir Leszek will examine th	e current and future



Sir Leszek will examine the current and future position of biomedical research in the United Kingdom. Reflecting on the enviable global position the UK currently holds in this field, and looking towards how this can be sustained in the future. Addressing key issues including; the sustainability of the current model of research and funding in the UK, the necessity of academic-industry interface and how the UK can continue to be a major global player despite competition.

18:00 – 19:30	Welcome Reception	

**BSDS** Annual Dinner

Central 2, Exhibition Hall

Manchester Art Gallery

19:30 - 23:00



# TUESDAY 6TH JULY – THE BRITISH SOCIETY OF CUTANEOUS ALLERGY

TIME	PROGRAMME VENUE
09:00 - 12:30	THE BRITISH SOCIETY OF CUTANEOUS ALLERGY CHARTER 3,4,5
CHAIRS	Dr Mark Wilkinson & Dr John McFadden
09:00	Prosser – White Oration <b>Hand eczema – diagnosis, treatment and prevention</b> Dr Tove Agner (Copenhagen, Denmark)
09:45	CD01 – Nine years' experience of patch testing to investigate footwear allergic contact dermatitis: can the distribution of rash help predict the cause of the dermatitis or the allergens involved? R.Y.P. Hunasehally, T.M. Hughes and N.M. Stone
09:55	CD02 – Allergic contact dermatitis to methylene-bis-benzotriazolyl tetramethylbutyl phenol <u>M. O'Connell</u> and M. Wilkinson
10:02	CD03 – A case report of cross-sensitization between latex, potato and yellow bell pepper: the latex-fruit syndrome and review of the literature V. Samarasinghe, G. Street, M.H. Beck, J.D.L. Williams
10.12	<b>CD04 – Allergic contact dermatitis to methyl hydroxystearate in a rubber</b> <b>respirator</b> <u>E. Benton</u> , I.R. White, J.M.L. White and J. McFadden
10:19	<b>CD05 – A retrospective review of patch test results in individuals working</b> <b>in the printing industry</b> <u>S. Ogden</u> , J. Newsham, M.H. Beck and J. Williams
10.29	<b>CD06 – The importance of patch testing, even in 'classical scenarios'</b> <u>F. Al-Niaimi</u> , J. Williams and R. Nalluri
10.36	COFFEE Central Hall
CHAIRS	Dr David Orton & Dr Jason Williams
11.05	<b>CD07 – Patch testing for perineal dermatitis: 13 years' experience</b> <u>M.A. McAleer</u> and J. Bourke
11.15	CD08 – A rare case of acquired leucoderma following patch testing to acrylate series <u>C. Kwok</u> , M. Wilkinson and S. Sommer
11.22	CD09 – The prevalence of allergic contact dermatitis remains high in patients with leg ulcers despite the widespread introduction of 'hypoallergenic' dressings <u>G. Kaushal</u> and S. Cooper
11.32	<b>CD13 – Severe allergic contact dermatitis from shoes due to dimethyl fumarate</b> <u>M. Alrawi</u> and J. Sansom



- 11.39 **CD11 Erythematous reactions on removing Scanpor® tape in patch testing are not necessarily caused by dermographism** <u>M. Simms</u>, I.R. White and J.M.L. White
- 11.46 **CD12 Investigating contact allergy to CS gas** <u>K. Bhargava</u>, P. Banerjee and I.R. White
- 11.53 **CD10 An outbreak of occupational allergic contact dermatitis to 2-N-octyl-4-isothiazolin-3-one among workers in an adhesive factory** <u>M.G. Khorasgani</u> and G. Johnston
- 12:03 **CD14 The role of patch testing in chronic urticaria** <u>A. Kai</u>, C. Grattan, I.R. White and J.M.L. White
- 12:10 **CD15 The role of patch testing in the management of oral lichenoid reactions of uncertain aetiology** <u>M. Lynch</u>, N. O'Rourke, A. Ryan, S. Flint, C. Healy, S.C.F. Rogers and P. Collins
- 12:17 **CD16 Allergic contact dermatitis to methylchloroisothiazolinone and ethylenediamine. Which paint is safe?** <u>D. Shah</u> and M.M.U. Chowdhury
- 12:24 **CD17 Photoallergic contact dermatitis to isoamyl methoxycinnamate in an organic sunscreen** <u>M. Ghazavi Khorasgania</u> and G. Johnston
- 12:34 **CD18 Retrospective review of 282 patients who were patch tested for vulval symptoms** <u>F. Al-Niaimi</u>, J. Williams and C. Pavey
- POSTERS **CD19 Occupational allergic contact dermatitis to artificial nails in a professional male guitarist** <u>R. Nalluri</u>, F. Al-Niaimi and J. Williams

**CD20** – **Allergic contact dermatitis to copolymers** <u>A. Kai</u>, M. Khorshid and J. McFadden

**CD21** – Acrylates tooth and nail: coexistent allergic contact dermatitis to acrylates present in desensitizing dental swabs and artificial fingernails <u>J.M.R. Goulding</u> and T.M. Finch

**CD22** – Sleepover dermatitis: allergic contact dermatitis to **2-mercaptobenzothiazole in an air mattress** <u>C. Allen</u>, S.M. Burge and S. Cooper

**CD23** – **Contact allergy to chromate in an infant** <u>R. Regester</u> and M. Wilkinson

CD24 – Nickel allergy and allergic contact dermatitis to embroidered Indian clothing

A. Woods and L. Ostlere



# TUESDAY 6TH JULY – BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY

TIME	PROGRAMME	VENUE			
09:00 - 12:45	BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY	EXCHANGE HALL			
CHAIR	Dr Pamela McHenry				
09:00	<b>PA01 – Oral corticosteroids are not required for the s</b> of kerions <u>L.E. Proudfoot</u> , M. Cunningham, E.M. Higgins and R. Morris-Jo	-			
09:10	<b>PA02 – To re-scrape, or not to re-scrape: that is the q</b> <u>L. Duckworth</u> , B. Kodz-Gibb and A. Abdullah	uestion			
09:20	<b>PA03 – The new face of congenital melanocytic naevi</b> <u>V. Kinsler</u> , A. Shaw and R. Hennekam				
09:30	<b>PA04 – Novel ABCA12 mutations in harlequin ichthyo</b> <b>clinical outcomes</b> <u>S. Rajpopat</u> , E. O'Toole and D. Kelsell	sis and a review of			
09:40	<b>PA05 – Hyper-IgE syndrome: how easy is it to diagnos</b> J. Kluk, H. Goodyear and A. Loffeld	e?			
09:50	<b>Guest Lecture What's new in vasculitis of the young</b> Dr Paul Brogan (London)				
10:30	Теа	Central Hall			
CHAIR	Dr Olivia Schofield				
11:05	PA06 – The use of etanercept in children and adolesce to-severe plaque psoriasis: a report of three successfu <u>S. Cheng</u> and R. Murphy				
11:15	<b>PA07 – A survey examining the use of phototherapy i</b> <b>population</b> <u>M. Walsh</u> , S. Dolman, G. Sharpe, T. Clayton and R.A.G. Parsle	•			
11:25	<b>PA08</b> – <b>Severity stratification of Children's Dermatolo</b> ( <b>CDLQI) scores</b> <u>A. Waters</u> , D. Sandhu, P. Beattie, F. Ezughah and S. Lewis-Jone				
11:35	<b>PA09</b> – The role of the school nurse in managing atop <u>A. Aslam</u>	pic eczema			
11:45	<b>PA10 – Shin pad eczema: an under-recognized phenor</b> <u>C. Roberts</u> , S. Lawton, J.S.C. English and J.C. Ravenscroft	menon?			
11:55	<b>PA16 – Discrete papular mucinosis, a rare subtype of myxoedematosus occurring in a teenage girl</b> <u>R.Y.P. Hunasehally</u> , R.G. Goodwin, L. Intzedy and I. Thompsor				



- 12:01 **PA12 Anti-IgE in the management of severe paediatric eczema unresponsive to conventional systemic therapy** S.M.H. Chan, P. Kane, <u>A.-M. Powell</u>, D.J. Atherton and G. Lack
- 12:07 **PA13 Transient aquagenic palmar hyperwrinkling: three paediatric cases** <u>A.V. Sears</u>, V.R. Doherty, O.M.V. Schofield and M.J. Tidman
- 12:13 **PA14 Novel heterozygous frameshift mutations of the desmoplakin gene presenting with hair shaft abnormalities and culminating in lethal cardiomyopathy** <u>P.D. Yesudian</u>, A.M. Christiano, E.J. Ladusans, S. Spinty, J. Gibbs, A. Fryer and S.S. Mendelsohn
- 12:19 PA15 An unusual cutaneous manifestation of immunodeficiency: disseminated BCGosis and axillary abscess associated with interleukin-12/ interferon- pathway deficiency <u>A. Mahto</u>, G. Tudor-Williams and C. Hardman
- 12:25 **PA11 Sole dermatitis in children: patch testing revisited** <u>M.I. Darling</u>, H.M. Horn, S.K.A. McCormack and O.M.V. Schofield

Close

Posters PA17 – A case series showing the range of cutaneous presentations of juvenile systemic lupus erythematosus <u>A. Patel</u> and R. Murphy

PA18 – Propranolol for ulcerated haemangioma in a preterm baby: our experience

R. Gulati and C. Jury

PA19 – Bleach baths using Milton® sterilizing fluid for recurrent infected atopic dermatitis

C. Vlachou, K. Batta, K. Pett and G. Nicholls

**PA20 – Acquired reactive perforating collagenosis in Down syndrome** <u>J. Hafiji</u>, E. Hook and N.P. Burrows

PA21 – A rare presentation of a systemic disease rarely seen in childhood: sarcoidosis

A. Fogo and E.M. Higgins

PA22 – Disseminated orf infection in a 13-year-old boy with atopic dermatitis

E. Higgins, M. Bennett, S. Curran, A. Murphy and T. Markham

PA23 – Poikilodermatous truncal eruption in a 15-year-old boy: a unique clinical presentation of macular arteritis <u>C. Cunningham</u> and B. O'Donnell

PA24 – An audit of adherence to the National Institute for Health and Clinical Excellence (NICE) guidelines on the management of atopic eczema in children

C. Devereux and S. Hoey

**PA25** – **Compositae allergy in two children with hand dermatitis** <u>D. Coates</u>, S. Cooper and S.M. Burge

**PA26** – The presence of IgE-mediated food allergy and poor weight gain in a series of children under 2 years of age with atopic eczema <u>A. Woods</u> and R.A. Marsden



# **TUESDAY JULY 6TH – DETAILED PROGRAMME**

TIME	CODE	PROGRAMME	VENUE
11:00 - 12:00		HISTORICAL SYMPOSIUM	EXCHANGE 4 & 5
	CHAIR	Dr Nick Levell	
11:00	H01	Niels Ryberg Finsen: the only dermatologis Nobel Prize for medicine L. Paul	st to be awarded the
11:15	H02	<b>A tribute to Robert Willan in Bloomsbury</b> <u>S. Walker</u>	Square
11:30		Guest Lecture <b>90 years on: Sir Archibald Gray, The Found</b> <b>1920 – 2010</b> Dr Sid Orpin (Solihull)	er of the BAD
12:00 – 13:00		Historical Symposium Lunch	Exchange 6
POSTERS	H03	<b>Doctors of the Wild Wart</b> H. Thomas and <u>P.D. Yesudian</u>	
	H04	The Weals of Time: a historical perspective <u>E. Borzova</u> , C. Grattan and N.J. Levell	e of chronic urticaria
	H05	Shedding some light on skin disease: three skin surface microscopy <u>U. Eke</u> and S. Orpin	e and a half centuries of
	H06	The bridge from west to east: Paulus Aegi M. Chriba and N.J. Levell	neta (AD 625–690)
	H07	<b>A. Bernard Ackerman (1936–2008): a Princeton tiger finally re</b> <u>A. Sherley-Dale</u>	
	H08	Healing votive offerings in dermatology S. Tzortzis and R. Arnott	
transplantation		The changing face of lupus: from wolf bite transplantation <u>C. Kasparis</u> and J. Gach	es to stem cell
	H10	<b>Erythema elevatum diutinum: the lost art</b> <u>T. Maruthappu</u> and S. Tharakaram	of clinical description
	H11	<b>Pellagra: the first published photosensitiv</b> <u>P. Wan</u> and A.V. Anstey	ity syndrome
	H12	German National Socialism: decline, desert P.D. Yesudian, P. Balasubramaniam and P. Yesud	
	H13	Changing patterns of U.K. dermatology pu G. Ali, A. Shipman and N.J. Levell	ıblications 1919–2009



TIME	PROGRAMME	VENUE	
08:00 - 09:00	Executive BSD Committee Meeting	Exchange 2	
09:30 – 12:30	Clinicopathological Cases, Joint meeting with the Exchange British Association of Dermatologists Auditorium		
12:30 – 13:00	Joint BAD/BSD Neil Smith LectureExchangeInterface dermatitis and connective tissue diseaseAuditoriumDr Martin Mihm (Boston, USA))Exchange		
14.30 – 15.00	BSD AGM	Charter 3,4,5	
15:00 – 18:00	BSD MAIN PROGRAMME	CHARTER 3,4,5	
	Chair: Dr Maureen Walsh		
15:00	<b>Review of vascular lesions with emphasis on childhoo</b> Dr Martin Mihm (Boston, USA)	d lesions	
15:45	Introduction and comment on posters		
15:49	<b>DP01 – Multicentric epithelioid haemangioendothelioma of the penis</b> <u>F. Al-Niaimi</u> , S. Shaktawat, G. Hall, L. McWilliam, V. Sangar and I.H. Chaudhry		
15:56	<b>DP02 – Painful mutilating ulceration of the dorsolateral foot in diplegics</b> <b>with acroangiodermatitis of Mali</b> J. Vyas, S. Howarth, D. Coleman, E. Calonje, N. Ivins, K.G. Harding and G.K. Patel		
16:03	DP03 – A congenital painful ulcerated vascular plaque angiomatous hamartoma requiring deep surgical exci <u>S. Rai</u> , V. Madan, P.J. August and L.A. Jamieson		
16:10 – 16:40	Coffee	Central Hall	
	Chair: Dr Saleem Taibjee		
16:40	<b>DP04 – Diffuse dermal angiomatosis: a rare and distin</b> <b>dermatosis of the breasts</b> <u>S. Rai</u> , Y. Mukasa, D. Fairhurst, W. Salman, W. Merchant and I		
16:47	<b>DP05</b> – <b>Unravelling cylindromas: insights into appendageal tumour</b> <b>patterning from patients with truncating CYLD mutations</b> <u>N. Rajan</u> , K. Gillinder, C. Lord, J.A.A. Langtry, J. Burn, A. Ashworth, B. Chaudhury and M. Sieber-Blum		
16:54	<b>DP06 – Follicular variant of squamous cell carcinoma:</b> J. Carter, T. Preece, S. Taibjee, S. Sanders and R. Carr	a series of 30 cases	
17:01	DP07 – With a clinical suspicion of melanoma or atypic the type of biopsy impact the efficient use of resource the pathologist to provide the pertinent information management of the patient? <u>C. Sladden</u> and R.I. Crawford	es and ability of	
17:08	<b>DP08 – Dermoscopy of fading naevi</b> <u>R. Vyas</u> , A. Oakley and M. Rademaker		



- 17:15 **DP09 Histopathological review of 78 cases of cicatricial alopecia at one U.K. centre** S.A. Thiryayi, M.J. Harries, E. White, C.E.M. Griffiths, R. Paus and I.H. Chaudhry
- 17:22 **DP11 Parastomal pyoderma gangrenosum successfully treated with adalimumab** A. Ryan, K. Sheahan and B. Kirby
- 17:29 **DP12 A novel case of follicular mucinosis following autologous stem cell transplant for multiple myeloma** <u>S. Cheng</u>, I.H. Leach and W. Perkins
- 17:36 **DP13 A review of 15 cases of cutaneous angioimmunoblastic T-cell lymphoma** <u>E. Benton</u>, B. Martin, K. Naresh and A. Robson
- 17:42 **DP14** Invasive ductal carcinoma and ductal carcinoma in situ arising within a naevus sebaceus of Jadassohn: the use of immunohistochemical markers to recognize invasion <u>L. Smith</u> and E. Husain
- 17:49 **DP15 Three cases of CD20+ primary cutaneous T-cell lymphoma** <u>B. Martin</u>, C. Stefanato, S.J. Whittaker and A. Robson
- 17:56 DP16 Lichen scrofulosorum-like clinical presentation with unusual histology
   M. Sivaramakrishnan, A. Mishra, A. Barbieri and P. Woo
- 18:03 Best presentation prize and close
- Posters **DP17 A painful nail** <u>R. Vyas</u>, D. Lamont and A. Yung

**DP18** – Necrolytic migratory erythema in a patient with pseudoglucagonoma syndrome due to a pancreatic carcinoid tumour <u>E.A. Langan</u>, L.A. Jamieson and H. Young

DP19 – Subcutaneous presentation of primary cutaneous follicle centre cell lymphoma: a taxonomic dilemma? <u>E. Benton</u>, A. Eichholz, S.J. Whittaker, S. Morris and A. Robson

**DP20** – **Goltz syndrome: a mild case with delayed diagnosis** <u>S.L. Chua</u>, M. Khan, C. Moss and J.C. Ravenscroft

**DP21** – Epstein–Barr virus-positive methotrexate-associated lymphoma in a patient with rheumatoid arthritis <u>E. Craythorne</u>, J. Scarisbrick and A. Robson

# DP22 – The t(14;18) translocation is rarely encountered in primary cutaneous follicle centre lymphoma

<u>A. Abdul-Wahab</u>, N. Agar, A. Robson, F. Child, J. Scarisbrick, M. Neat, T. Mitchell, S. Tang, S. Morris and S.J. Whittaker

# DP23 – Waldenström's macroglobulinaemia with amyloid deposition presenting in the ears


R. Healy, M. Saha, A. Rohatiner and R. Cerio

# DP24 – Granulomatous T-cell lymphoma in association with yellow nail syndrome

N. Anjum and I.C. Pearson



# WEDNESDAY 7TH JULY – OVERVIEW





# WEDNESDAY JULY 7TH – DETAILED PROGRAMME

TIME	CODE	PROGRAMME		VENUE	
08:00 – 18:00		Registration desk open		Central Foyer	
08:45 – 10:00		Scientific Session – Submitted Papers		Exchange	
	CHAIRS	Auditorium Dr Robert Chalmers & Dr Ian Coulson			
08:45	0-08	A retrospective study of methotrexate for moderate-to-severe atopic eczema S.J. Meggitt, C. Smith, G. Petrof and N.J. Reynolds			
09:00	0-09	thiopurine metabolite azathioprine	e of the thiopurine methyl assays in the treatment of Mould, N. Barlow and J. Berg		
09:15	0-10	Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: the value of an oral scoring methodology for monitoring therapeutic response J.S. Wee, P.J.S. Shirlaw, S.J. Challacombe and J.F. Setterfield			
09:30	GL03	Guest Lecture – Introduced by Dr Stephen Jones <b>Update on cutaneous side effects of chemotherapy</b> Professor Jean Bolognia (New Haven, USA)			
		102	The lecture will focus on thre	e topics:	
		(1) the cutaneous side effects of epide growth factor receptor (EGFR) inhibito particular the papulopustular eruption treatment;			
		(2) the mucocutaneous side effects of multi-kinase inhibitors, focusing on imatinit			
			(3) the unifying concept of to chemotherapy.	0	
10:00 – 11:00		Coffee & Poster Viewing		Central 2, Exhibition Hall	
11:00 – 13:00		Annual General Meetin	g (members only)	Exchange Auditorium	
13:00 – 14:30		Lunch & Exhibition		Central 2, Exhibition Hall	
13:15 - 14:15		JANSSEN CILAG SATELLI	TE SYMPOSIUM (PAGE 57)	EXCHANGE HALL	
13:15 - 14:15		LA ROCHE POSAY SATE	LLITE SYMPOSIUM (PAGE 57	') CHARTER 3,4,5	

14:30 - 1	8:00		BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY	EXCHANGE HALL
14:30 – 1	8:00		BRITISH PHOTODERMATOLOGY GROUP	CENTRAL 5,6,7
14:30 – 15	5:30		Scientific Session – Medical Dermatology & Submitted Papers	Exchange Auditorium
		CHAIRS	Prof Nick Reynolds & Dr John O'Driscoll	
14	4:30	MD01	<b>What's new in Immuno-bullous Diseases</b> Dr Richard Groves (London)	
15	5:00	0-11	A case series of 16 patients treated with rituximation immunobullous disease C.L. Martyn-Simmons, M. Saha, M.M. Black and R.W. Grov	-
15	5:15	0-12	<b>Erectile dysfunction in patients with psoriasis: incr</b> <b>prevalence, an unmet need and a chance to interve</b> <u>J.M.R. Goulding</u> , C.L. Price, C.L. Defty, C.S. Hulangamuwa I. Ahmed	ene
15	5:30	MD02	<b>Polycystic Ovary Syndrome</b> Professor Adam Balen (Leeds)	
16:00 – 16	6:30		Tea & Exhibition	Central 2, Exhibition Hall
16:30 – 18	8:15		Scientific Session – Medical Dermatology & Submitted Papers Continued	Exchange Auditorium
		CHAIRS	Dr Eileen Parry & Dr Jane Sterling	
16	6:30	MD03	<b>Dermatological aspects of HIV and an update on tl testing</b> Dr David Paige (London)	he issues around
17	7:00	013	Hypopigmented mycosis fungoides: a study of the clinicopathological, immunophenotypic and progn <u>E.C. Benton</u> , A.M. Robson and E.M. Wain	ostic features
17	7:15	0-14	<b>The incidence of second primary skin cancer in an</b> <u>A. Pring</u> , J. Verne and D.A.R. de Berker	English region
17	7:30	MD05	<b>Emergency Dermatology</b> Dr Cameron Kennedy (Bristol)	
18	8:00	MD06	e-dermatology: BAD and e-LfH launch their joint e- Dr Robert Charles-Holmes (Warwick) & Dr Jane Sterling (C	,
18	8:15		e-dermatology launch reception	Exchange 3



14:30 – 16:30		Joint Session – British Association of Dermatologists and British Dermatological Nursing Group	Charter 3,4,5
	CHAIRS	Dr Harvinder Ghura & Sheila Robertson	
14:30	JM01	<b>Top tips - Psoriasis and the biologics</b> Dr David Burden (Glasgow)	
14:50	JM02	<b>Top tips for PDT</b> Paula Oliver (Worthing)	
15:10	JM03	<b>Top tips Paediatrics</b> Dr Tim Clayton (Manchester)	
15:30	JM04	<b>Top tips for treating hyperhidrosis</b> Tracey Wheeler (Bristol)	
15:50	JM05	<b>Top tips Surgery</b> Dr Harvinder Ghura (Manchester)	
16:10	JM06	<b>Top tips for treating lymphoedema</b> Elizabeth Coveney (Swansea)	
19:30 – 00:00		Annual Dinner	Manchester Town Hall



## WEDNESDAY 7TH JULY – BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY

TIME	PROGRAMME	VENUE
14:30 - 18:00	BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY	EXCHANGE HALL
14:30 – 15:50	Session 1	
CHAIR	Dr Graeme Stables	
14:30	<b>DS01 – Basal cell carcinomas excision margins: primar</b> <u>A. Alsharqi</u> , N. Wilson and P. De Mozzi	y vs. secondary care
14:40	<b>DS02 – Melanocytic lesions of unknown malignant poto outcome in 35 patients</b> <u>H. Al-Rawi</u> , A. Husain and C.M. Lawrence	tential: features and
14:50	DSO3 – A traumatic pseudoaneurysm of the superficia referred as a lipoma <u>G. Sega-Hall</u> , R. Turner and R. Asher	l temporal artery
15:00	DSO4 – The Imre and perialar crescentic advancement reconstruction of upper cheek defects and those invol sidewall and/or dorsum <u>W. Hussain</u> , E. Tan, N. Mortimer, C. Gleeson and P. Salmon	
15:10	<b>DS05</b> – The utility of the transposition-rotation flap or reconstruction of complex auricular defects <u>W. Hussain</u> , C. Gleeson, N. Mortimer and P. Salmon	f Weerda for the
15:20	<b>DS06 – A novel application of the W-plasty transposit</b> <b>the anterior temple</b> <u>H. Al-Rawi</u> and J.A.A. Langtry	ion flap for defects of
15:26	DSO7 – Free cartilage grafts to repair ala nasi defects: graft or secondary intention healing J. Shelley, C. Lawrence and J.A.A. Langtry	with concurrent skin
15:32	DSO8 – Three cases of linear basal cell carcinoma treat micrographic surgery <u>G. Becher</u> , A. Affleck, C.J. Fleming and A.E. Evans	ted by Mohs
15:38	<b>DS09 – Collapse during scalp tumour extirpation: a ca</b> <b>Mohs micrographic surgeon</b> <u>W. Hussain</u> , P. Salmon, C. Gleeson and N. Mortimer	utionary tale for the
15:44	DS10 – Case report and video demonstration of bilate transposition flap to treat a challenging basal cell car forehead <u>R. Verdolini</u> , N. Clayton and C.L. Lowry	
15:50 – 16:20	Break	Exhibition Hall

WEDNESDAY 7TH JULY – BSDS PROGRAMN



- CHAIRS Dr Raj Mallipeddi & Dr Tamara Griffiths
  - 16:20 **DS11 A study of the efficacy of carbon dioxide and pigment-specific lasers in the treatment of medium-sized congenital melanocytic naevi** <u>V. Madan</u>, J. Ferguson and P.J. August
  - 16:26 **DS12 Hairy intraoral flap: an unusual indication for laser depilation** <u>T.N. Shim</u>, N. Talsania, K. Chittari, C. Avery, S. Lanigan and A. Abdullah
  - 16:32 **DS13 The increasing use of fat grafting** <u>S. Tzortzis</u> and V. Vijh
  - 16:38 **DS14 Botulinum toxin A for focal hyperhidrosis of the face and** <u>amputation stump</u> <u>L. Atkinson</u>, S. George and B. Shergill
  - 16:44 **DS15 Plication of the superficial musculoaponeurosis facilitates tensionfree closure of medium- to large-sized defects on the temple and cheek** <u>R.R. Rahim</u>, R.B.M. Barry and T.H. Nguyen
- 16:50 17:40 Session 3
  - CHAIR Dr Sandeep Varma
  - 16:50 **DS16 The use of printed digital photographs as a substitute for conventional schematic Mohs maps: our experience of 80 cases** <u>B. Moriarty</u>, F. Deroide and E.D. Seaton
  - 16:56 **DS17 Comparison of ex vivo optical coherence tomography with conventional frozen-section histology for visualizing basal cell carcinoma during Mohs micrographic surgery** <u>D. Cunha</u>, T. Richardson, N. Sheth, G. Orchard, A. Coleman and R. Mallipeddi
  - 17:02 **DS18 Mohs micrographic surgery in a U.K. teaching hospital: audit of the first 6 years (2003–09) and introduction of a new minimum dataset** <u>A. Waters</u>, L. Macfarlane, A.E. Evans, A. Affleck and C.J. Fleming
  - 17:08 **DS19 Mohs micrographic surgery for dermatofibrosarcoma protuberans** <u>S. Rajpara</u>, S. Varma, G. Perks and W. Perkins
  - 17:14 **DS20 Mohs micrographic surgical excision for atypical fibroxanthoma at critical sites** <u>R.R. Rahim</u> and J.A.A. Langtry
  - 17:20 **DS21 Salvage Mohs micrographic surgery for highly destructive facial nonmelanoma skin cancer. Is it of benefit?** <u>B. Wynne</u>, M. McMenamin, C. Timon and P. Ormond
  - 17:26 **DS22 Meticillin-resistant Staphylococcus aureus prevalence in a Mohs micrographic surgery service** <u>A. Foulkes</u>, S. Dunn, C.M. Lawrence and J.A.A. Langtry
  - 17:32 **DS23 Mohs micrographic surgery for dermatofibrosarcoma protuberans: experience in a large regional centre** <u>W.P. Tan</u>, J. Mckenna, A. Robson and R. Mallipeddi

18:00 – 18:30 BSDS AGM

Exchange Hall



#### Posters DS24 – Successful treatment of pulsed dve laser recurrent granuloma faciale with the carbon dioxide laser

V. Madan and P.J. August

DS25 - Adenoid cystic carcinoma vs. adenoid basal cell carcinoma: a Mohs challenge

L.E. Proudfoot, I. Roxanis and S. Bashir

DS26 – Audit: infection rates following dermatological surgery <u>A. Fogo</u> and S. Bashir

DS27 – Follow-up preferences for patients with basal cell carcinoma: the basis for modelling clinical practice and commissioning D.A.R. de Berker, V. Poirier and A. Takwale

DS28 – Audit of 2-week-wait referrals: how does tertiary referral influence management?

S. Anthony, C. Vlachou, M. Murdoch, F. Tatnall, K. Batta and V. Brown

DS29 – Do skin cancer multidisciplinary teams make any difference in the management of incomplete or narrowly excised basal cell carcinomas? C. Kasparis, L. Yalakki and I. Ahmed

DS30 - Serial excision: a useful technique to achieve good cosmetic outcomes when excising large benign naevi S. Ng, V. Madan and A. Morris

DS31 – A proof of concept study to investigate the efficacy of microneedle arrays in local anaesthetic administration to human skin M.A. McAleer, A.Moore, A.Crean, C.O'Mahoney and J. Bourke

#### DS32 – Malignant cytology in washings of Mohs micrographic surgery instruments

B. Moran, B. Wynne, S. Thomas, M. Griffin, M. McMenamin and P. Ormond

#### DS33 – Dermatological surgery in the community: are the guidelines being followed?

M.G. Khorasgani, S. Payne and M. Khorshid

DS34 – Toluidine blue in Mohs surgery: another indication and its advantage in a case of a primary morphoeic basal cell carcinoma coexisting with B-cell marginal zone lymphoma K. Chittari, I. Leach, W. Perkins and S. Varma

DS35 – Rhinophyma and basal cell carcinoma

R. Kwah and C.M. Lawrence

DS36 - Closure of combined nasal ala-perialar defect with the Shark Island pedicle flap

R. Kwah and J.A.A. Langtry

DS37 – Swab technique A. Foulkes, M. Narayanan, J.A.A. Langtry and C.M. Lawrence

DS38 – The head-tilt manoeuvre

V. Madan and P.J. August

DS39 – Superficial parotidectomy and the use of silastic sheet: a potential method to protect against buccal nerve and parotid duct injury during Mohs surgery for mid cheek skin cancer

K. Chittari, A. Graeme Perks and W. Perkins

## WEDNESDAY JULY 7TH BRITISH – PHOTODERMATOLOGY GROUP

TIME	PROGRAMME	VENUE
14:30 - 18:00	BRITISH PHOTODERMATOLOGY GROUP	CENTRAL 5,6,7
CHAIRS	Prof Anthony Young & Dr David Taylor	
14:30	Is UVR-induced immunosuppression of clinical sig Professor Mary Norval	nificance?
15:05	UVA and the heart. Is NO news good news? Dr Richard Weller	
15:40	PD01 – Xeroderma pigmentosum presenting with sunburn reactions: first correlation between com acute effect of sunlight <u>H. Fassihi</u> , S. Walker, D. McGibbon, H. Fawcett, A. Lehma	plementation group and
15:55	<b>PD02 – UVA1 phototherapy: the experience of on</b> <u>S. Attili</u> , R.S. Dawe, S. Ibbotson and J. Ferguson	e centre
16:10	Tea & Coffee Break	Exhibition hall
CHAIRS	Prof Anthony Young & Dr David Taylor	
16:45	<b>PD03</b> – The melanocyte stimulating hormone and conveys photoprotection in solar urticaria <u>A.K. Haylett</u> , Z. Nie, M. Brownrigg, R. Taylor and L.E. Rho	-
17:00	<b>PD04 – Solar urticaria confined to areas of bruisi</b> <u>B. Esdaile</u> , S.A. Grabczynska and S. George	ng
17:15	<b>PD05 – Solar urticaria: an analysis of trends and t</b> <b>Irish population</b> <u>S.M. Verma</u> , L. Gaynor and G.M. Murphy	treatment efficacy in the
17:30	PD06 – Sealed-unit semiautomated minimum erver allow for safe and convenient MED testing prior to B phototherapy R.Y.P. Hunasehally, A.V. Anstey and C. Edwards	

17:45 Close of meeting



#### Posters **PD07 – Familial porphyria cutanea tarda associated with the HFE gene mutation**

M. Lynch, A. Ryan and P. Collins

**PD08** – **Treatment of cutaneous sarcoid with topical gel photochemotherapy** <u>I. Staveley</u>, C. Gleeson, N. Morar and C. Bunker

**PD09** – **Comparative efficacy of photochemotherapy and narrow band ultraviolet B radiation in the treatment of severe plaque type psoriasis** <u>V. Malhotra</u>

**PD10 – A rarely reported cause of drug-induced photoaggravated eczema** <u>F. Al-Niaimi</u> and C.C. Lyon

PD11 – Bath psoralen plus ultraviolet A for hidradenitis suppurativa: a review of 13 patients


M.S. Shareef and R.S. Dawe

PD-12 – Comparison of clinical efficacy and cost-effectiveness of photochemotherapy vs. photochemotherapy with natural sunlight in chronic plaque psoriasis in Indian patients

S. Khandpur, K. Aggarwal, N. Khanna, V.K. Sharma and C.S. Pandav



## THURSDAY 8TH JULY – OVERVIEW





## THURSDAY 8TH JULY – DETAILED PROGRAMME

TIME	CODE	PROGRAMME	VENUE
08:00 – 18:00		Registration desk open	Central Foyer
08:30 - 12:15		Professors & Registrars Forum	Exchange Auditorium
08:30 – 10:25	CHAIRS	Dr Richard Groves & Prof Eugene Healy	
08:30	RF01	<b>Panton–Valentine leucocidin (PVL)-positive Staphy</b> <b>cause recalcitrant skin infections in dermatology</b> A. Fogo, <u>E. Craythorne</u> , J. Wade, R. Hay and R. Morris-Jon	patients
08:45	RF02	<b>Clinical and genetic predictors of treatment responses</b> <b>narrowband ultraviolet B radiation for chronic pla</b> C. Ryan, <u>P. Collins</u> , B. Kirby and S. Rogers	
09:00	PR01	<b>Translational research in photodermatology</b> Professor Alex Anstey (Newport)	
09:20	RF03	<b>Response to hydroxychloroquine in patients with</b> <b>erythematosus</b> <u>S. Wahie</u> , M. Goodfield¬, A.J. Carmichael, M.M. Carr, A. I S.K. Jones, C.R. Lovell, N. Reynolds and S.J. Meggitt	-
09:35	RF04	<b>IgA from two patients with erythema elevatum di</b> <b>associated with IgA antineutrophil cytoplasmic an</b> <b>superoxide production and degranulation of neut</b> <u>R. Simpson</u> , S.J. Alvaro, M. Morgan, A.B. Alexandroff, C. S and K.E. Harman	itibody stimulates rophils in vitro
09:50	PR02	<b>Academe</b> Professor Christopher Griffiths (Manchester)	
10:10	RF05	Functional failure of lymphatics in human primary V. Akhras, R. Ramakrishnan, A. Stanton, R. Mellor, R. Levio	
10:25 – 11:10		Coffee & Exhibition	Central 2, Exhibition Hall
		Professors & Registrars Forum continued	
11:10 – 12:15	CHAIRS	Dr Mark Goodfield & Dr Richard Warren	
11:10	RF06	HLA class II allele distribution in pemphigus foliac Europeans and Indo-Asians from the U.K. <u>M. Saha</u> , K.E. Harman, N.J. Mortimer, V. Bind, M.M. Black R. Vaughan and R.W. Groves	
11:25	PR03	<b>Genodermatoses</b> Professor Edel O'Toole (London)	



11:45 **RF07 Cutaneous Lymphoma International Prognostic Index (CLIPI)** <u>E.C. Benton</u>, S. Crichton, N.S. Agar, P. Fields, E. Wedgeworth, T.J. Mitchell, M. Cox, S. Ferreira, A.M. Robson, E. Calonje, C.M. Stefanato, E.M. Wain, B. Wilkins, A. Dean, K. Webb, J. Scarisbrick, S. Morris and S.J. Whittaker

12:00 **RF08 BSID Best paper:** Dysregulated tropomyosin receptor kinase (Trk) signalling in CYLDtrunc/trunc tumours <u>N Rajan</u>, CJ Lord, O Clewes, J Burn, M Sieber-Blum and A Ashworth

12:15 GL04 Arthur Rook Oration Guest Lecture – Introduced by Dr Stephen Jones Neutrophilic vascular reactions Dr Joseph Jorizzo (Winston-Salem, USA)



In a 1988 CME article in the JAAD, we speculated that common aspects of pathogenesis, patient education and treatment existed for certain dermatoses characterized by neutrophilic dermal infiltrates that had previously been considered separately. Viewed 22 years later the concept of neutrophilic vascular reactions has become well accepted. Even though dramatic new research breakthroughs have been lacking, an update is warranted.

13:00 – 14:30		Lunch & Exhibition	Central 2, Exhibition Hall
13:15 – 14:15	SCHERI	NG-PLOUGH SATELLITE SYMPOSIUM (PAGE 58)	EXCHANGE HALL
14:30 – 18:00		Continuing Professional Development Session	Exchange Auditorium
	CHAIRS	Dr Robert Charles-Holmes & Dr Stephen White	
14:30 – 15:00	CPD01	<b>Biologics, which/when</b> Dr Catherine Smith (London)	
15:00 – 15:30	CPD02	<b>Connective Tissue Diseases</b> Dr Chris Lovell (Bath)	
15:30 – 16:00	CPD03	<b>CAMS (Clinical Audit Management Software) prese</b> Dr Claire Fuller (Canterbury)	entation



Guest Lecture – Introduced by Dr Mark Goodfield **Current thinking in medical education** Professor Sarah Thomas (Leeds)



The lecture as part of the Continuing Professional Development session will provide an overview of the educational process including the role of the Lead Dean and the role of Medical Education England and will allow the opportunity to consider the following current topical areas in medical education:

- EWTR
- Workforce Data
- Financial constraints on health economics – 2011 onwards
- Quality Metrics
- Training interfaces between community and secondary care

16:30 – 17:00		Coffee Break	Exchange Hall
	CHAIRS	Prof Alex Anstey & Prof Edel O'Toole	
17:00 – 17:30	CPD04	What's new in Photodermatology Professor Lesley Rhodes (Salford)	
17:30 – 18:00	CPD05	<b>Update on paediatric dermatology</b> Dr Mary Judge (Salford)	
18:00 – 18:15		<b>President's Address</b> Dr Stephen Jones (Wirral)	
18:15		Close of meeting	



# NOTES



## **ADDITIONAL MEETINGS**

<b>TUES 6TH JUI</b>	LY	
TIME	MEETING	ROOM
10:00 - 12:00	British Teledermatology Society	Exchange 3
	For further information please contact: Saul.Halpern@medway.nhs.uk	
17:30 – 18:30	Dermatology Teachers	Central 6
	Expert lecture series launch	
	E-learning programme for dermatology	
	AOB	

TIME	MEETING	ROOM
13:00 – 14:00	British Society for Medical Dermatology Committee Meeting	Exchange 1
17:00 – 18:30	Senior Skin Group	Exchange 4
	For further information please contact maggie@kirkup.plus.com	
18:15 – 19:00	e-dermatology Launch Reception	Exchange 3

ТІМЕ	MEETING	ROOM	
07:30 – 08:30	<b>Christian Medical Fellowship</b> If you would like to reserve a place at the breakfast please contact: conference@bad.org.uk	Exchange 2 / 3	

## POSTERS

The posters are situated within the exhibition area Central 2 and there will be a dedicated poster viewing hour on Wednesday July 7th from 10:00 - 11:00. All presenting authors have been asked to stand by their poster at this time.

## **BRISTOL CUP POSTERS**

### **Case series and cases / CPCs**

P-1 Cutaneous leiomyoma: the dermatological presentation of hereditary leiomyomatosis and renal cell cancer

M. Durkie, R. Pollitt, L. Chapman, A. Dalton and G. Sobey

- P-2 An unusual first presentation of Darier disease with psychosis and myositis K.W. Tan and R.S.P. Lim
- P-3 Axillary (and facial) acne agminata mimicking hidradenitis suppurativa A. Martin, G. Becher and G. Dawn
- P-4 Review of patients with dual diagnosis of vulval lichen planus and vulval lichen sclerosus (lichen sclerosus/lichen planus overlap) C.M. Green, J. Gibbs, J. Guest and J. Paterson
- P-5 Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream B. Arun, J.M. Pearson and R.J.G. Chalmers
- Incontinentia pigmenti and squamous cell cancer P-6 J. Mikeljevic and C.C. Lyon
- P-7 Microsphaeropsis arundinis: a rare cause of cutaneous infection T.N. Win, T. Chave and E. Johnson
- Idiopathic hyperkeratosis of nipple and areola **P-8** R. Fatima and G. Dawn
- A family with Fabry disease diagnosed by a single angiokeratoma P-9 A. Corry, C. Feighery, D. Alderdice, F. Stewart, M. Walsh and O.M. Dolan
- Lacrimal canalicular duct scarring in patients with lichen planus P-10 N.K. Webber, F.M. Lewis, J.F. Setterfield and S. Neill
- P-11 An unusual cause of neonatal scarring J. Felton and C.R. Darley
- P-12 Familal pemphigus vulgaris M. Saha, M.M. Black, B. Bhogal and R.W. Groves
- P-13 Atypical cutaneous lymphoproliferative disorder, the presenting feature of a patient subsequently diagnosed with human immunodeficiency virus infection L. Stewart, Z. Twaji and C. Owen
- An unusual cause of alopecia, rash and retinitis P-14 J. Felton, L. Atkinson and C. Degiovanni
- P-15 Sniffing out bed bugs: a clinical case and update J. Felton and L. Atkinson



- P-16 A case series of three patients with erythema elevatum diutinum in association with paraproteinaemia and IgA antineutrophil cytoplasmic antibodies R. Simpson, S.M. Crichlow, A.B. Alexandroff and K.E. Harman
- P-17 Howel-Evans syndrome: cutaneous presentation associated with internal malignancy N.Y.Z. Chiang and J. Verbov
- P-18 A case-control study demonstrating drug associations in patients diagnosed with bullous pemphigoid <u>A. Lloyd-Lavery</u>, K. Taghipour and F.T. Wojnarowska
- P-19 A rare cause of panniculitis requiring a novel therapy <u>F. Al-Niaimi</u> and C.C. Lyon
- P-20 A case of unilateral leg ulcers secondary to Brown-Sequard syndrome <u>J.S. Wee</u>, L. Yeo, G. Petrof, S.M. Langan and C.H. Smith
- P-21 First report of lichen sclerosus in three successive generations S.K. Goolamali, S.I. Goolamali and H. Gordon
- P-22 Schöpf–Schulz–Passarge syndrome: a case report <u>T. Patel</u> and S. Loghdey
- P-23 Dermatitis herpetiformis arising within vitiligo in the presence of multiple autoimmune conditions A.E. Macbeth, L. Igali, N.J. Levell and G.W.M. Millington
- P-24 Lichen planopilaris following hair transplantation and facelift surgery L. Lyne, M.J. Harries, I.H. Chaudhry, B. Farjo, N. Farjo, D. Cadore de Farias, A. Tosti, C.E.M. Griffith s and R. Paus
- P-25 Severe penile lymphoedema complicating hidradenitis suppurativa: two cases N. Desai, <u>G. Petrof</u>, E. Healy and P.S. Mortimer
- P-26 Localized scleroderma (morphoea) with retinal and cerebral involvement J. Kluk and J. Bhat
- P-27 Morphoea secondary to radiation injury J. Crawley, M.Y. Walsh and K.E. McKenna
- **P-28** A review of orofacial granulomatosis in a specialist dermatology/oral medicine clinic <u>P.D. Yesudian</u>, B.P. Rajlawat and E.A. Field
- P-29 Neurofibromatosis type 1 with extensive cutaneous disease burden and dysmorphic features caused by complete gene deletion: a specific subtype requiring close surveillance

E. Higgins, B. Cullen, M. Bennett and P.A. Marren

P-30 Recessive inheritance of mild epidermolysis bullosa simplex W. Szczecinska, A. Terron-Kwiatkowski, D. Baty and C. Moss

#### **Education & Training**

- P-31 Future proofing clinical meetings: demonstrating educational efficacy <u>A. Weidmann</u>, T.P. Kingston and M. Singh
- **P-32 Dermacademy: a unique e-learning tool for dermatology clinicians** <u>A.A. Atwan</u> and M.L. Gonzalez
- P-33 Learning dermatology: how can we do it better? <u>M. Singh</u>, L.E. Rhodes and T. Dornan



P-34 Integrating computer assisted instruction in traditional undergraduate dermatology promotes adult learning

R. Gamanya and B. Stephen

- P-35 Assessments of trainees: still an evolving process? <u>G. Wylie</u> and A. Drummond
- P-36 Does undergraduate dermatology education affect junior doctors' diagnostic and therapeutic skills? B. Zafiriu and P.D. Yesudian

#### **Inflammatory Skin Diseases**

- P-37 Many patients with psoriasis need long-term specialist dermatology care <u>C. Kwok</u> and M. Shah
- P-38 Does incidence of male genital dermatoses vary with age? <u>M. Shah</u>
- P-39 Assessing quality of life of family members of patients with inflammatory skin diseases using two preference-based measures O. Williams and M.K.A. Basra
- P-40 Abstract withdrawn
- P-41 Severe psoriasis has a greater negative effect on quality of life than previously appreciated: a U.K. web-based patient survey A.V. Anstey, G. Edwards and A. Lass
- P-42 Ets-1 transcription factor and matrix metalloproteinases: critical role in repigmentation of vitiligo D. Parsad, R. Kumar and A.J. Kanwar
- P-43 Measuring the severity and impact on quality of life of infants with atopic dermatitis in a dedicated clinic K. Ahmad, J. Saunders and B.C.P. Ramsay
- P-44 The influence of chronic skin diseases on major life-changing decisions as a parameter for the assessment of long-term impact <u>Z.U. Bhatti</u>, S. Salek and A.Y. Finlay
- P-45 The patient experience: a survey of members of the Psoriasis Association <u>G. Edwards</u>, A.K. Gilbert and H. McAteer
- P-46 Validation of a psoriatic arthritis screening questionnaire in rheumatology and dermatology outpatients
   C. Marshall, M. Bukhari and P.V. Harrison
- P-47 Strengthening the Dermatology Life Quality Index's clinical meaning: minimal clinically important difference of the scores M.K.A. Basra, L. Camilleri, S. Salek and A.Y. Finlay
- P-48 Localized staphylococcal scalded skin syndrome in five patients with atopic dermatitis S.I. Goolamali, C. Haddadeen, J.D. Creamer, R. Hay, E.M. Higgins and R. Morris-Jones
- P-49 Extradomain A-positive fibronectin positive feedback loops in psoriasis J. McFadden, B. Baker, A. Powles and L. Fry
- P-50 Patch testing for peristomal dermatitis among patients with a stoma: results of our 10 years' experience F. Al-Niaimi and C.C. Lyon



P-51 Early maladaptive schemas and psychological distress in outpatients with psoriasis and atopic eczema

A. Mizara, L. Papadopoulos and S.R. McBride

- P-52 Dose rate-dependent upregulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 by ultraviolet A in human keratinocytes J. Whiteside, A. Ridley, T.J. McMillan, S. Allinson and S. Long
- P-53 Cicatricial alopecias: a retrospective analysis of 92 cases from one U.K. centre M.J. Harries, I.H. Chaudhry, R. Paus and C.E.M. Griffiths

#### **Medical Dermatology & Therapy**

- P-54 A randomized bilateral vehicle-controlled study of effornithine cream combined with laser treatment vs. laser treatment alone for facial hirsutism in women <u>M. Arora</u>
- P-55 Nonclinical influences in dermatology decision making: a study of clinicians' perspective <u>F. Hajjaj</u>, S. Salek, M.K.A. Basra and A.Y. Finlay
- P-56 Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience S. Chenq, V. Smith and R. Murphy
- P-57 Simple, effective keloid surgery within the dermatology department D. Odunsi and R. Morris-Jones
- P-58 Interventions for vitiligo: a Cochrane systematic review <u>M. Whitton</u>, M. Pinart, J. Batchelor, C. Lushey, J. Leonardi-Bee and U. Gonzalez
- P-59 A 'real world' observational study of adalimumab in patients with moderate to severe psoriasis who have failed on etanercept therapy: a retrospective case cohort study <u>R. Woolf</u>, K. Robertson, C.H. Smith and J.N.W.N. Barker
- P-60 Efficacy and safety of acitretin in three fixed doses of 25 mg, 35 mg or 50 mg in patients with severe plaque-type psoriasis: a randomized, double-blind, parallelgroup, dose-ranging study S. Dogra, A. Jain and I. Kaur
- P-61 Old problem, new technique: introducing a novel bandaging technique for the management of lower leg ulceration <u>S. Wong</u>, R. Bull, A. Hopkins, M. O'Brien, F. Worboys, I. Farrelly and W. George
- P-62 Paradoxical induction of psoriasis by antitumour necrosis factor therapy: a case series <u>T. Patel</u>, V. Ghura, A. Messenger, P. Marks and H. Ramsay
- P-63 Attitudes towards use of topical treatments during Ramadan: perspective of U.K. Muslim patients <u>T. Patel</u> and V. Ghura
- P-64 Dapsone as adjuvant treatment in chronic ordinary urticaria: positive implications for quality of life N. Rajan, S. Darne, A. Ah-Weng and A.J. Carmichael
- P-65 Chronic truly idiopathic urticaria and autoimmune urticaria: are they the same? <u>S. Yadav</u>, A.J. Kanwar, D. Parsad and R.M. Walker
- P-66 Ustekinumab safety update: cumulative experience from longer-term follow-up of patients treated in the ustekinumab psoriasis clinical development programme K. Gordon, C. Leonardi, <u>C.E. Griffiths</u>, P.O. Szapary, N. Yeilding, M.C. Hsu, N. Wasel, J. Prinz and K. Reich



- P-67 Mucous membrane pemphigoid successfully treated with the combination of mycophenolate mofetil and dapsone H. Al-Rawi, K.S. Staines and P.J. Hampton
- P-68 Preliminary studies to inform the STOPGAP trial: how the pilot work influenced the main trial design F. Craig, A.D. Ormerod, K. Thomas and H. Williams
- P-69 Ustekinumab in patients with psoriasis who have failed all other biologic agents <u>W. Malik</u> and M.J.D. Goodfield
- P-70 Effectiveness of parenteral methotrexate in recalcitrant dermatoses: a worthwhile consideration prior to biologics? P.D. Yesudian
- P-71 High-performance liquid chromatography assay for the detection of diphencyprone and the metabolite diphenylacetylene in serum and urine following topical application for the treatment of alopecia areata Y. Mukasa, A. Drbal, N. Anyakoha, D. Fairhurst, S.P. Macdonald Hull and A. Nicolaou
- **P-72** Successful treatment of severe chronic urticaria with omalizumab <u>H. Fassihi</u>, J.M. White, E. Benton, G. Morgan, M.W. Greaves and C.E.H. Grattan

#### **Melanoma & Skin Cancer**

- P-73 An audit of melanoma referrals from general practitioners to a district general hospital dermatology department <u>P. Kerr</u>, M. Clement, C. Powell and S. Munn
- P-74 How does melanoma recurrence present? Findings from the North Wales melanoma database D. Shah, A. Sarpal and R. Lister
- P-75 Sunscreen use and availability in the U.K.: a cost-based analysis <u>C. Wilkinson</u> and T. Lucke
- P-76 Sunnier European countries have a lower melanoma mortality A.R. Shipman and N.J. Levell
- **P-77** Management of cutaneous melanoma in primary care in the East of England <u>G. Ali</u>, J. Garioch, E. Tan, C. Waddy, M. Moncrieff, S. Gibbs and V. Gudi
- P-78 Management and outcomes of 28 cases of Merkel cell carcinoma treated in our centre, 2003 2008 N.C. Chetty, L. Igali, M. Moncrieff and J. Garioch
- **P-79** Factors associated with incomplete excision of basal cell carcinomas <u>Y.L. Teoh</u>, S.M. Halpern and L. Shall
- P-80 Measures of ultraviolet radiation in the South West <u>C. Wilkinson</u>, M. Saunders and A. Curnow
- P-81 Alemtuzumab-resistant Sézary syndrome responding to zanolimumab <u>V. Shpadaruk</u>, A.B. Alexandroff, M. Bamford, M.J.S. Dyer and R. Burd
- P-82 CDKN2A and CDK4 mutations in two unrelated British melanoma-prone families and implications for genetic testing J. Lai-Cheong, G. Pichert, K.M. Acland and S. Whittaker
- P-83 Analysis of copy number changes in primary cutaneous malignant melanoma, with and without metastases, by multiplex ligation-dependent probe amplification <u>A.-M. Martin</u>, S. Lake, A. Taktak, P. Brackley, P. Hold, N. Leonard and S. Coupland

- P-84 Audit of completeness of cancer registration for basal cell carcinoma and its impact on use for quality assurance I. Pignatelli, V. Poirier, D.A.R. de Berker and J. Verne
- P-85 Can healthy adults maintain sufficient vitamin D levels without ultraviolet radiation? Implications for prevention of skin cancer S.A. Rice, M. Carpenter, L.M. Vearncombe, A. Fityan, J. Baird and E. Healy
- P-86 Socioeconomic status and prognostic factors in cutaneous melanoma M.I. Darling, C. Leitch, D. Brewster, L.A. Bhatti, S. Jensen and V.R. Doherty
- P-87 A retrospective network study of the latest Royal College of Pathologists' minimum dataset for malignant melanoma S. Pruneddu, D. Piras, U. Igbokwe, N. Wijesuriya, F. Cottoni and R. Cerio
- P-88 Single-centre retrospective review of patients with melanoma receiving whole brain radiotherapy for metastatic disease S.H. Hussain, K.A. Zaki, S. Crusz and P. Corrie
- P-89 Two-week wait skin cancer referral outcomes: differences in management between plastic surgery and dermatology <u>E. Ogden</u> and J. Schofield

#### **Service Issues**

- P-90 The development of the National Ehlers–Danlos Syndrome Specialist Service J. Bowen, J. Tocher, J. Lemmon, R. Pollitt, A. Dalton and G. Sobey
- P-91 Do dermatologists help patients? Using patient-reported outcome measures in a district general hospital N. Harper, C. Sharpe, K. Horton, E. Whyles, H. Bunn, K. Shepherd and N. Hepburn
- P-92 Improving risk management in dermatology: retrospective review and prospective recommendations
  <u>D.J. Gawkrodger</u>
- P-93 Evaluation of the compliance with NICE guidance on the use of biologics in the management of severe psoriasis A.P. Bewley, R. Cerio, M. Clement, S. Hunt, T. Lucke, R. Ratnavel, S. Walton and S. Marshall
- P-94 Dermatitis artefacta: outcome is better with a multidisciplinary dermatology/liaison psychiatry team approach <u>P. Mohandas</u>, A.P. Bewley and R. Taylor
- P-95 Is surgery carried out in secondary care dermatology departments a cost-efficient service? <u>M. Clement</u>
- **P-96** The national tariff fails to compensate adequately for dermatology services <u>H.M. Liew</u> and M. Shah
- P-97 Referrals, red legs and reflective learning: a 12-month audit of inpatient dermatology referrals at a district general hospital <u>A. Weidmann</u>, T. Griffiths and T.P. Kingston
- **P-98** Low-priority procedures: do they need to be top priority? J.R. Felton, L.R. Atkinson, S.M.C. George and E.K. Derrick
- P-99 Are NICE skin cancer guidelines being followed in primary care? A re-audit to review changes in practice in an inner city setting <u>P. Dewan</u>, E. Panagou, S. Kajen, A.P. Bewley, A. Sahota and K. Gibbon



P-100 The impact of a new model of acute care delivery on the emergency dermatology referrals

C. Vlachou, T. Lwin, F. Tatnall, K. Batta, M. Murdoch and J. Dyche

- P-101 Legal claims in English dermatological practice <u>S. Ong</u> and I.H. Coulson
- P-102 Under-reporting of invasive malignant melanomas in North East of Scotland <u>F. Hussain</u>, F. Muller and E. Husain
- P-103 Nonattendance at dermatology outpatient clinics S.M.C. George, L.R. Atkinson, J.R. Felton, D.A. Harrison, E.K. Derrick and C.R. Darley
- P-104 Retrospective assessment of the diagnostic accuracy of an admitting diagnosis of cellulitis and appropriateness of antibiotic therapy <u>C.L. Defty</u>, J.M.R. Goulding, I. Ahmed and J.E. Gach
- P-105 Two-year retrospective review of a transplant-dermatology surveillance clinic in the management of renal transplant recipients
  V. Samarasinghe, S. Russell, V. Madan and J.T. Lear
- P-106 Full skin examination is essential in the assessment of dermatology patients: an audit of 494 patients B. Moran, I. McDonald and B. Kirby
- P-107 Retrospective analysis of a psychodermatology service <u>A. Mizara</u> and S. McBride
- P-108 Completeness of basal cell carcinoma excisions in an English region <u>I. Pignatelli</u>, V. Poirier, D.A.R. de Berker and J. Verne
- P-109 Wound infection rates and revalidation. Who will be measuring our infection rates? B. Esdaile and E. Williamson
- P-110 The impact of designated dermatology beds on the Dermatology Life Quality Index score of patients before and after their admission <u>B. Esdaile</u> and R. Ratnavel

#### History

- P-111 Sir Archibald Gray 1880–1967: founding father of the British Association of Dermatologists S. Orpin
- P-112 A history of Ehlers–Danlos syndrome <u>G. Sobey</u> and M. Shah
- P-113 The 1962 smallpox outbreak: lessons for today P. Trehan, J. Wright and A. Wright



## **TUESDAY JULY 6TH – SATELLITE SYMPOSIUM**

TIME	PROGRAMME	VENUE	
13:15 - 14:15	PFIZER SATELLITE SYMPOSIA	EXCHANGE HALL	
	Long term management of Psoriasis		
Chair	Professor Jonathan Barker, London		
	Long Term efficacy of biologics: How important is this to the long term management of Psoriasis Robert Strohal, Austria		
	Learning's from the biologic registry data: How important is the emerging safety data for th James Galloway, Manchester	ne biologics	
	Psoriasis & co-morbidities: What are the most important co-morbidities the should consider and manage Richard Warren, Manchester	dermatologist	

## **TUESDAY JULY 6TH – SATELLITE SYMPOSIUM**

TIME	PROGRAMME	VENUE
13:15 - 14:15	ABBOTT SATELLITE SYMPOSIA	CHARTER 3,4,5
	Choices in Psoriasis – Triggered by Failure or Motivated by	Outcomes?
Chair	Dr David Burden, Glasgow	
13:15	<b>Introduction</b> Dr David Burden (Glasgow)	
13:20	<b>The cumulative impact of psoriasis as a trigger for treatme</b> Professor Jemec (Denmark) TBC	ent
13:35	Interactive case study of the psoriasis patient treatment pa Dr Ruth Murphy (Nottingham)	athway
14:05	<b>Questions</b> Dr David Burden, Professor Jemec & Dr Ruth Murphy	
14:15	Close	



## WEDNESDAY JULY 7TH – SATELLITE SYMPOSIUM

TIME	PROGRAMME	VENUE	
13:15 - 14:15	JANSSEN CILAG SATELLITE SYMPOSIA	EXCHANGE HALL	
		NALL	
	Biologics in Psoriasis: Putting the Pharmacological Puzz	le Together	
Chair	Professor Chris Griffiths, Manchester		
Presentation 1	The half life of biologics: what does this mean in clinical practice		
	Co-Presenters:		
	Prof. Kristian Reich, Hamburg, Germany		
	DI Hugil Davis, Centocol USA		
Presentation 2	The clinical impact of IL-12/IL-23 blockade in psoriasis: efficacy update for ustekinumab treatment	3 year safety and	
Presentation 2	and Dr Hugh Davis, Centocor USA <b>The clinical impact of IL-12/IL-23 blockade in psoriasis:</b>	3 year safet	

## WEDNESDAY JULY 7TH – SATELLITE SYMPOSIUM

TIME	PROGRAMME	VENUE
13:15 - 14:15	LA ROCHE-POSAY SATELLITE SYMPOSIA	CHARTER 3, 4, 5
	Optimising UVA Photoprotection	
Moderator	Prof. John Hawk, London	
13:15-13:18	Welcome & Introduction Prof. John Hawk, London	
13:18 – 13:35	<b>Ultraviolet Radiation Effects on Skin</b> Dr Henry Lim, Detroit	
13:35 – 13:50	<b>The Need for Skin UVA Photoprotection</b> Dr. Gillian Murphy, Dublin	
13:50 – 14:05	<b>Ultimate UVA Photoprotection for the Photodermatoses</b> Dr André Rougier, Paris	
14:05 – 14:15	<b>Panel Discussion with Audience Participation</b> Prof. John Hawk, Dr Henry Lim, Dr Gillian Murphy, Dr André Rougie	er
	<b>Summary and Conclusions</b> Prof. John Hawk, London	

57

SATELITTE SYMPOSIUM



## THURSDAY JULY 8TH – SATELLITE SYMPOSIUM

#### TIME PROGRAMME

VENUE

## 13:15 – 14:15 SCHERING-PLOUGH SATELLITE SYMPOSIA

EXCHANGE HALL

#### "This house believes we can manage psoriasis without using biologics."

Join the debate

Introduction Jon Snow and Chair Veteran journalist and broadcaster

> 4 key speakers in the debate faculty will then present compelling arguments for and against the motion, with up-to-date reflections on the management of psoriasis as they see it:

**1st Proposer** Professor Chris Griffiths, Manchester


**1st Opposer** Professor Jonathan Barker, London

**2nd Proposer** Dr Brian Kirby, Dublin

**2nd Opposer** Dr David Burden, Glasgow



## **MAP OF MANCHESTER**





## **CES MEETINGS CALENDAR**

SEPTEMBER 2010	<b>Learning Teaching &amp; Assessment Course</b> Venue: BAD House Date: 1st – 2nd September
	Dermdoc
	Venue: BAD House
	Date: 20th September
	SpR Training Event
	Venue: BAD House
	Date: 30th September – 1st October
OCTOBER 2010	Management of Non-Melanoma Skin Cancer in the UK Venue: The Royal Society of Medicine
	Date: 8th October
NOVEMBER 2010	Clinical Dermatology Update Meeting for

Clinical Dermatology Update Meeting fo Staff and Associate Specialist Doctors Venue: Radisson SAS, Manchester

Date: 4th – 5th November

**The Annual UK Dermatology Course for Consultants** Venue: The Hilton Paddington Hotel, London Date: 26th – 27th November

For Further Details on any of these meetings please contact:

- Conference & Event Services; 4 Fitzroy Square London W1T 5HQ
- Email: conference@bad.org.uk
- Tel: 020 7391 6358





# NOTES





### ECZEMA IS ALWAYS WAITING TO ATTACK

La lasta

#### FOR LONG-TERM ECZEMA CONTROL YOU NEED TO ACTIVELY MANAGE THE UNDERLYING INFLAMMATION.<sup>1</sup>

Atopic eczema flares can be managed in the short-term, but the threat of another flare is always lurking under the surface. New twice-weekly Protopic offers an effective way to control eczema in the long-term by treating the sub-clinical inflammation between flares.<sup>2</sup> It prevents flares and prolongs flare-free intervals in adults and children with moderate to severe eczema.<sup>2</sup>

#### SO DON'T WAIT FOR THE FLARE, USE TWICE-WEEKLY PROTOPIC TO CONTROL MODERATE TO SEVERE ECZEMA IN THE LONG TERM.\*

\*Patients should have had an initial response to an acute exacerbation with Protopic twice daily (max. 6 weeks' treatment).

**REFERENCES:** 1. Leung DYM et al. *J Clin Invest* 2004; 113(5): 651-657. 2. Protopic Summary of Product Characteristics, 2009. **PRESCRIBING INFORMATION**: Protopic\* 0.03% ointment (tacrolimus monohydrate). Protopic\* 0.1% ointment (1acrolimus monohydrate) **ACTIVE INGREDIENT** Protopic\* 0.03% ointment (1g) contains 0.3mg of tacrolimus as tacrolimus monohydrate (0.03%). Protopic\* 0.1% ointment (1g) contains 0.3mg of tacrolimus as tacrolimus monohydrate (0.03%). Protopic\* 0.1% ointment (1g) contains 1.0mg of tacrolimus as tacrolimus monohydrate (0.1%). **HERAPEUTIC INDICATIONS** Protopic\* 0.03%: - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. Protopic\* 0.03%, 0.1%cmaintenance treatment of moderate to severe atopic dermatitis in prevention of flares and prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolinuus ointment (lesions cleared, almost cleared or mildly affected). **DOSAGE AND METHOD OF USE** Protopic\* should be tinitated by physicians with experience in the diagnosis and treatment of atopic dermatikis. Protopic\* a be used for short-term and intermittent long-term treatment. Itreatment should not be applied under occlusion. Protopic\* is not recommended for use in children below the age of 2 years until further data are available. Specific studies have not been conducted in elderly patients. However clinical experience has not shown the necessity for any dosage ad

April

PBO1

Protopic<sup>®</sup> should be applied once a day twice weekly (e.g. Monday and Thursday) to commonly affected areas to prevent progression to flares. Between applications there should be 2-3 days without Protopic<sup>®</sup> treatment. Adult patients (16 years of age and above) should use Protopic<sup>®</sup> 0.1%, children (2 years of age and above) should use the lower strength Protopic<sup>®</sup> 0.3%. If signs of a flare reoccur, twice daily treatment should be reinitiated. After 12 months, a review of the patients' condition should be conducted by the physician and a decision taken whether to continue maintenance treatment. In children, this review should include suspension of treatment to assess the need to continue this regimen and to evaluate the course of the disese. **UNDESIRABLE EFFECTS** Very common: Burning sensation (which tends to resolve within one week of starting treatment), pruritus. Common: Sensation of warmth, erythema, pain, irritation, paraesthesia and rash at site of application. Alcohol intolerance (ficcial flushing or skin irritation after consumption of an alcoholic beverage). Patients may be at an increased risk of herpes viral infections (herpes simplex [cold sores], eczema herpeticum, Kaposi's varicelliform eruption) and folliculitis. Uncommon: acne. During post-marketing experience: Rosacea. Also, cases of malignancies, including cutaneous and other types follymphoma, and skin cancers, have been reported in patients using tarcinlimus ointment. Application site impetigo and application site infections occurred more frequently in a study of maintenance treatment in adults and children. Prescribers should consult the summary of product characteristics in relation to other side effects. **PRECAUTIONS FOR USE** Protopic\* on the developing immune system of children, especially the young, has not yet been established and this should be taken into account when prescribing to this age group. Exposure of the skin to sunlight should be minimised and the use of ultraviolet (UV) light from a solarium, therap



astellas

Twice weekly for long-term eczema control\*

been reported. Patients with atopic dermatitis treated with Protopic<sup>\*</sup> have not been found to have significant systemic tarcolimus levels. Lymphadenopathy was uncommonly (0.8%) reported in clinical trials. The majority of these case related to infections (skin, respiratory tract, tooth) and resolved with appropriate antibiotic therapy. Patients who receive Protopic<sup>\*</sup> and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves. Lymphadenopathy present at initiation of therapy should be investigated and kept under review. In case of persistent lymphadenopathy, the aetiology of the lymphadenopathy should be investigated in the absence of a clear aetiology for the lymphadenopathy should be used with caution in patients with hepatic failure. Protopic<sup>\*</sup> should be used with caution in patients with thepatic failure. Protopic<sup>\*</sup> should be used with caution in patients with thepatic failure. Protopic<sup>\*</sup> should not used with caution unless clear and the reviewed by the physician. Protopic<sup>\*</sup> should not be used dring pregnarcy unless clearly necessary and is not recommended when breast-feeding. The safety of Protopic<sup>\*</sup> has not been established in patients with generalised erythroderma. Protopic<sup>\*</sup> is unlikely to have an effect on the ability to drive or use machines. CONTRAINDICATIONS Hypersensitivity to macrolides in general, to tarcolimus or to any of the excipients. INTERACTIONS Because of the optential risk of vaccination failure, vaccination should be audimistered prior to commencement of treatment, or during a treatment-free interval with a patients with depended out and the concommant systemic administration of known CYP3A4 inhibitors in patients with dueby Protopic<sup>\*</sup> 10.4% ointment £19.44.303 (tube), £35.46 (609 tube), £35.46 (600 tube) Protopic<sup>\*</sup> 10.4% ointpreserversed and for the fully protopic<sup>\*</sup> on the used aliable Protopic<sup>\*</sup> 10.4% ointpreserversed and the protopic<sup>\*</sup> 10.4% ointpreserversed and prior to commencement of treatment. Or during a treatment-free interval wi

Adverse events should be reported. Reporting forms and information can be found at <u>www.yellowcard.gov.uk</u>. Adverse events should also be reported to Astellas Pharma Ltd - 0800 783 5018

## Golf Day at the Belfry Friday 1st October 2010

## Fancy a round of golf?

The British Skin Foundation is looking for keen individuals who like the idea of swinging for a great cause.

Register now for 'Swing for Skin', a fantastic opportunity to play at the world renowned Belfry golf course in the West Midlands and a great way to support the only charity in the UK dedicated to fundraising for skin disease research.

Play at the 18 holes of the **Brabazon course** and the driving range are included in the price as is a buffet dinner.

There will also be complimentary longest drive and nearest the pin competitions on the day. The event promises to be a huge amount of fun and a fantastic competition!

## Sign up now, spaces are limited!

Start time: 10.30am - 1.20pm (depending on tee off time)

To register, or for more information, call the BSF events team on 0207 391 6352 email bsfevents@bad.org.uk or visit www.britishskinfoundation.org.uk





Registered Charity No. 313865